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ABSTRACT

A method of treating a neurological condition in a patient,
the method including the step of applying an electrical
stimulation from conductors to the patient's head at a
stimulation application site. In some embodiments, the elec
trical stimulation includes a composite electrical signal
further comprising at least one signal form configured to
provide long-term treatment of the neurological condition
and at least one signal form configured to provide analgesia
for short-term pain relief. The invention also provides an
electrical stimulation apparatus having an electrical signal
generator adapted to provide an electrical signal form con
figured to provide long-term treatment of a neurological
condition and to provide an electrical signal form configured
to provide analgesia for short-term pain relief.
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Apparatus for providing an electrical signal form for
long-term treatment of a neurological condition
Apparatus for providing an electrical signal form to
provide analgesia for short-term pain relief

Fig. 3
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METHODS AND APPARATUS FOR
ELECTRICAL STIMULATION
INCORPORATION BY REFERENCE

0001 All publications and patent applications mentioned
in this specification are herein incorporated by reference to
the same extent as if each individual publication or patent
application was specifically and individually indicated to be
incorporated by reference.
FIELD

0002 The present invention relates generally to methods
and apparatus for electrically stimulating a tissue. More
specifically, the present invention relates to methods and
apparatuses for using electrical stimulation to treat fibro
myalgia and other neurological conditions involving central
pain, central sensitivity and abnormal brain neural network
connectivity.
BACKGROUND

0003 Electrical stimulation is known to alter the activity
of the brain and modulate neurotransmitter activity, both of
which are capable of providing therapeutic effects in both
nociceptive pain conditions and central pain conditions. The
use of electrical stimulation to treat pain and other neuro
logical conditions is described in U.S. Pat. No. 7,715,910;
U.S. Pat. No. 8,494,625; US Patent Publ. No. 2011/
0307029; and WO 2013/169838. The disclosures of these
publications are incorporated herein by reference.
0004 Nociceptive pain is known to arise from stimula
tion of peripheral nerve endings. The peripheral nociceptive
signal is transmitted through the spinal cord to the brain,
where it is processed through numerous pain-processing
networks. Descending pathways from the brain to the spinal
cord Subsequently modulate pain signals, thereby increasing
or decreasing pain perception.
0005. However, it is also known that enhanced activation
of central pain-processing pathways and networks, through
mechanisms such as neuroplastic changes in central neu
ronal activity and neural network connectivity, can lead to
spontaneous pain in the absence of peripheral nociceptive
input. When this occurs, pain is said to have “centralized'.
which results in lower pain thresholds, secondary hyperal
gesia in uninjured areas, and Sustained pain potentiation.
Brain-related centralized pain is thought to play a prominent
role in chronic pain conditions.
0006 Centralized pain is generally thought of as an
outcome of central sensitivity (CS), which is also known as
central sensitization, central augmentation, and central
hypersensitivity among other terms. CS mechanisms in the
brain have been implicated in the pathology of allodynia,
which is the term used to describe a condition where pain is
caused by a stimulus that does not normally provoke pain.
CS mechanisms in the brain have also been implicated in
hyperalgesia, which is the term used to describe a condition
in which pain perceived from a stimulus is greater than what
would normally be expected from that stimulus. Put simply,
in central sensitivity the brain magnifies painful stimuli and
eventually magnifies even associated non-painful stimuli. As
pointed out in Latremoliere and Woolfe (1), because CS
results from changes in the properties of neurons in the
central nervous system, the pain is no longer coupled, as
acute nociceptive pain is, to the presence, intensity, or
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duration of noxious peripheral stimuli arising from both
neuropathic and inflammatory sources. Further, in chronic
pain conditions the increased excitability caused by CS far
outlasts the initiating noxious stimulus, that is, the nocice
ptive input that causes the pain to occur in the first place.
0007. Before CS was discovered, typically only two
models of pain were contemplated. The first is the afore
mentioned nociceptive pain model, by which specific pain
pathways are activated by peripheral pain stimuli, and the
amplitude and duration of the pain experienced is deter
mined entirely by the intensity and timing of the peripheral
pain inputs. The second model contemplates gate controls in
the central nervous system that open and close, thus enabling
or preventing pain. Medical Science now recognizes CS as
a third and unique model that contemplates neuroplastic
changes in the functional properties and network connec
tivity of the central nervous system. For example, the level
of resting brain activity within multiple networks (e.g.,
functional network connectivity and effective network con
nectivity) is now known to be associated with spontaneous
pain in patients having centralized pain (2, 3). CS leads to
reductions in pain threshold, increases in the magnitude and
duration of responses to noxious input, and permits normally
innocuous inputs to generate pain sensations. In addition, CS
is also believed to be relevant in Somatic symptoms asso
ciated with painful conditions, including but not limited to
fatigue and sleep disorders.
0008. The brain's role in CS is being increasingly
revealed and understood in neuroscience, due in large part to
the advent of functional brain imaging technologies. For
example, Lee et al. (4) used functional magnetic resonance
imaging (fMRI) to examine the extent to which brain
activity contributes to the maintenance of CS in humans.
When the intensity of pain during CS was matched to the
intensity of pain during normal states, activity within the
brainstem, including the mesencephalic pontine reticular
formation and the anterior thalami, remained at an increased

level during CS. Regarding brain areas related to the con
sequence of increased pain perception during CS, cortical
activity, mainly in the primary somatosensory area, has been
significantly correlated with the intensity of pain attributable
to both the force of noxious stimulation used, and the state

in which noxious stimulation was applied.
0009 Borsook et al. (5) reviewed the literature on brain
activity using neuroimaging technologies. Their review
details evidence of alterations in multiple sub-cortical and
cortical processing mechanisms. Those alterations include
sensory, emotional/affective, cognitive, and modulatory sys
tems that are present in chronic pain. The authors note these
findings provide evidence that increases understanding of
the importance of the role of numerous brain regions in the
centralization of pain and the contributions of those regions
to the altered brain states associated with chronic pain
conditions. Similarly, Schweinhardt and Bushnell (6)
reviewed neuroimaging evidence of the active and enhanced
modulatory role that the brain plays in pain processing in
chronic pain patients. Schweinhardt and Bushnell also cite
findings that brain activations in chronic pain involve brain
circuitry not normally activated by acute nociceptive pain.
0010 Because of this emerging understanding, the role of
CS is increasingly being shown to be pathological in seem
ingly unrelated chronic pain conditions and syndromes
including fibromyalgia, complex regional pain syndrome,
phantom pain, and migraine headaches. Yunus (7) identifies
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no less than 14 common syndromes that lack structural
pathology yet have CS as a common mechanism. These
conditions further include chronic fatigue syndrome, irri
table bowel syndrome, tension-type headaches, temporo
mandibular disorder, myofascial pain syndrome, regional
soft-tissue pain syndrome, restless leg syndrome, periodic
limb movements in sleep, multiple chemical sensitivity,
primary dysmenorrhea, female urethral syndrome, intersti
tial cystitis, and post-traumatic stress disorder. Yunus also
notes that CS may play a significant role in the pain
associated with depression and in Gulf War Syndrome.
0011 Giesecke et al. (8) used fMRI to demonstrate
augmented central pain processing in patients with idio
pathic chronic low back pain and fibromyalgia. Indeed,
when equal levels of mechanical pressure intended to elicit
a painful response were applied to patients and to normal
controls, patients with chronic low back pain and fibromyal
gia experienced significantly more pain and showed more
extensive, common patterns of neuronal activation in pain
related cortical areas of the brain than did the controls. Thus,

CS may play an important role in persons with chronic low
back pain that persists without identifiable physical pathol
Ogy.

0012. The role of CS in persistent inflammatory condi
tions is also gaining recognition. In Gwilym et al. (9), fMRI
illustrated significantly greater brain activation in osteoar
thritis (OA) patients in response to stimulation of their
referred pain areas (i.e., areas where pain persists but do not
exhibit OA or related inflammation) compared with healthy
controls, and the magnitude of this activation positively
correlated with the extent of neuropathic-like elements to the
patient’s pain. The role of CS in osteoarthritis has been the
subject of several other investigations (10, 11, 12). As
detailed in Imamura et al. (13), the refractory, disabling pain
associated with knee OA is usually treated with total knee
replacement. However, a comparison of OA patients with
healthy normal controls showed patients with knee OA had
significantly lower pressure pain thresholds (PPT) over
widespread evaluated structures beyond the knee. The lower
PPT values were correlated with higher pain intensity,
higher disability scores, and with poorer quality of life. This
Suggests that pain in these patients might be more associated
with CS than with peripheral inflammation and injury. As the
authors point out, the implications of the role of CS, and its
potential for modulation, may provide exciting and innova
tive cost effective therapeutic tools to control pain, reduce
disability, and improve quality of life in knee OA patients.
0013 Yet, the treatment of CS is a challenging task. As
stated by Latremoliere and Woolfe (1), “The complexity is
daunting because the essence of central sensitization is a
constantly changing mosaic of alterations in membrane
excitability, reductions in inhibitory transmission, and
increases in Synaptic efficacy, mediated by many converging
and diverging molecular players on a background of phe
notypic Switches and structural alterations. Some centrally
acting pharmaceutical agents such as gabapentin (14.15),
ketamine (16), propofol (17) and anti-tumor necrosis factor
alpha (TNF-alpha) therapy (18), just to name a few, have
evidence of efficacy in treating CS. The patent literature has
examples in the art of pharmaceutical use as a therapeutic
agent for treating CS. For example, the use of dimiracetam
for treatment of hyperalgesia and allodynia caused by cen
tral sensitization in chronic pain has been taught. Further, the
use of compounds associated with (R)-2-acetamido-N-ben
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Zyl-3-methoxypropionamide has been taught to treat central
neuropathic pain, including “neurological disorders charac
terized by persistence of pain and hypersensitivity in a body
region.”
0014) Another relevant consideration is that analyses of
numerous brain imaging and functional measures, including
electroencephalographic (EEG) measures (19), have been
shown to produce measures related to brain networks and
functional connectivity that correlate to findings produced
by fMRI imaging (20). Thus, the presence of brain activity
associated with CS, and hence centralized pain, can be
determined using EEG measures and analysis.
0015. In addition to abnormalities in brain neural network
connectivity, it is also known that a number of neurotrans
mitters are involved in the processing of both central pain
and nociceptive pain. In some cases, certain neurotransmit
ters augment the processing of pain and are therefore
associated with increased pain. In other cases, certain neu
rotransmitters reduce the processing of pain, and are there
fore associated with decreased pain.
0016. The following citations are incorporated by refer
ence in their entirety:
00.17 1. “Central sensitization: a generator of pain hyper
sensitivity by central neural plasticity'. Latremoliere A,
Woolf C.J. J. Pain. 2009 September; 10(9):895-926.
0018 2. “Intrinsic brain connectivity in fibromyalgia is
associated with chronic pain intensity”. Napadow V.
LaCount L. Park K, As-Sanie S, Clauw DJ, Harris R. E.

Arthritis Rheum. 2010 August: 62(8):2545-55.
0019. 3. “Disrupted functional connectivity of the pain

network in fibromyalgia”, Cifre I, Sitges C, Fraiman D,

Muñoz M A. Balenzuela P. González-Roldán A, Marti
nez-Jauand M. Birbaumer N. Chialvo DR, Montoya P.
Psychosom Med. 2012 January: 74(1):55-62.
0020 4. “Identifying brain activity specifically related to
the maintenance and perceptual consequence of central
sensitization in humans', Lee MC, Zambreanu L, Menon
D K, Tracey I. J Neurosci. 2008 Nov. 5; 28(45): 1142-9.
0021 5. “A key role of the basal ganglia in pain and
analgesia—insights gained through human functional
imaging, Borsook D, Upadhyay J, Chudler E. H. Becerra
L. Mol Pain. 2010 May 13: 6:27.
0022 6. “Pain imaging in health and disease—how far
have we come?”, Schweinhardt P. Bushnell M. C. J. Clin
Invest. 2010 Nov. 1; 15(11):3788-97.
0023 7. “Fibromyalgia and overlapping disorders: the
unifying concept of central sensitivity syndromes”. Yunus
MB. Semin Arthritis Rheum. 2007 June; 36(6):339-56.
0024 8. “Evidence of augmented central pain processing
in idiopathic chronic low back pain'. Giesecke T. Gracely
RH, Grant MA, Nachemson A, Petzke F. Williams DA,
Clauw DJ. Arthritis Rheum. 2004 February; 50(2): 613
23.

0025 9. “Psychophysical and functional imaging evi
dence Supporting the presence of central sensitization in a
cohort of osteoarthritis patients', Gwilym S. E. Keltner J
R, Warnaby CE, Can AJ, Chizh B, Chessell I, Tracey I.
Arthritis Rheum. 2009 Sep. 15: 61 (9):176-34.
0026 10. “Lessons from fibromyalgia: abnormal pain
sensitivity in knee osteoarthritis, Bradley L. A. Kersh B
C, DeBerry J. J. Deutsch G, Alarcón G. A. McLain D A.
Novartis Found Symp. 2004; 260:258-70.
0027 11. “Sensitization in patients with painful knee
osteoarthritis', Arendt-Nielsen L, Nie H, Laursen M B,
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Laursen B. S. Madeleine P. Simonsen O H, Graven

Nielsen T. Pain. 2010 June; 149(3):573-81.
0028 12. “Pain mechanisms in osteoarthritis: under
standing the role of central pain and current approaches to
its treatment'. Mease PJ. Hanna S, Frakes E. P. Altman R

D. J Rheumatol. 2011 August; 38(8): 1546-51.
0029, 13. “Impact of nervous system hyperalgesia on
pain, disability, and quality of life in patients with knee
osteoarthritis: a controlled analysis”. Imamura M.
Imamura S. T. Kaziyama H. H. Targino RA, Hsing W T.
de Souza L. P. Cutait M M, Fregni F, Camanho G L.
Arthritis Rheum. 2008 Oct. 15: 59(10): 1424-31.
0030) 14. “Pharmacological modulation of pain-related
brain activity during normal and central sensitization
states in humans', Iannetti G. D., Zambreanu L, Wise RG,

Buchanan T.J. Huggins J P Smart T. S. Vennart W. Tracey
I. Proc Natl AcadSci USA. 2005 Dec. 13; 102(50): 18195
2OO.

0031) 15. “Chronic oral gabapentin reduces elements of
central sensitization in human experimental hyperalge
sia'. Gottrup H, Juhl G. Kristensen AD, Lai R, Chizh B
A, Brown J. Bach F W. Jensen TS. Anesthesiology. 2004
December: 101(6):350-8.
0032) 16. “Pharmacodynamic profiles of ketamine (R)and (S)- with 5-day inpatient infusion for the treatment of
complex regional pain syndrome', Goldberg ME, Tori
man MC, Schwartzman RJ, Mager DE, Wainer I W. Pain
Physician. 2010 July; 13(4):379-87.
0033 17. “Analgesic and antihyperalgesic properties of
propofol in a human pain model, Bandschapp O. Filitz, J.
Ihmsen H. Berset A, Urwyler A, Koppert W. Ruppen W.
Anesthesiology. 2010 August; 8(2):421-8.
0034. 18. “TNF-alpha and neuropathic pain—a review”.
Leung L, Cahill C M. J Neuroinflammation. 2010 Apr. 16;
7:27.

0035. 19. “Functional connectivity: the principal-compo
nent analysis of large (PET) data sets, Friston KJ, Frith
CD, Liddle P F, Frackowiak R. S. J. Cereb Blood Flow
Metab 1993: 13:5-14.

0036 20. “Electrophysiological signatures of resting
state networks in the human brain'. Mantini D, Perrucci
MG, Del Gratta C, Romani G. L., Corbetta M. Proc Natl

Acad Sci USA. 2007 Aug. 7: 104(32):2670-5.
SUMMARY OF THE DISCLOSURE

0037. The use of amplitude-modulated, pulse-width
modulation signals to treat neurological dysfunction via
stimulation of the brain is described, e.g., in U.S. Pat. No.
7.715,910. Clinical tests have shown that specific electrical
stimulation parameters—including waveform parameters,
treatment protocols and stimulation sites—can provide sig
nificant therapy benefits. These discoveries have also led to
the development of stimulation systems particularly Suited
to providing efficacious electrical stimulation therapy.
0038. In the following description of the disclosed meth
ods and apparatus, the term "centralized pain' is intended to
mean any form of pain, whether chronic or acute, that is
enhanced in its characteristics; Such as magnitude, duration
and scope; due to abnormal brain activity associated with
pain processing, or abnormalities involving neurotransmit
ters associated with pain. Such brain activity may include,
but is not limited to, central sensitivity and network con
nectivity. Such neurotransmitters may include, but are not
limited to, serotonin, norepinephrine, glutamate, N-Methyl
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D-aspartic acid, Substance P, gama-aminobutyric acid, vari
ous nucleotides and dopamine.
0039. The term “central sensitivity” is intended to mean
any central nervous system condition pathologically related
to hyperalgesia, allodynia, reductions in pain threshold,
increases in the magnitude and duration of responses to
noxious input, results in normally innocuous inputs to gen
erate pain sensations, or results in non-painful symptoms
associated with increases in central nervous system respon
siveness. Central sensitivity is also known by alternate terms
that include but are not limited to “central sensitization',

“central pain', 'central augmentation,” and “central hyper
sensitivity”.
0040. The terms “network connections” and “network
connectivity” are intended to mean various forms of rela
tionships between neural networks in brain regions involved
in processing of information Such as pain. For example,
“functional connectivity” refers to a statistical correlation
between the activities of different brain regions. “Effective
connectivity” denotes not simply a statistical but a causal
influence between two brain regions.
0041. The terms “treat” or “treating” are intended to
mean the act of reducing, making less severe, mitigating,
alleviating, or eliminating a condition and/or its symptoms
for any period of time.
0042 Except where the context requires otherwise, the
term “comprise' and variations of the term, such as “com
prising”, “comprises” and “comprised are not intended to
be exclusive. Where, for example, a form of the word
“comprise' is used to refer to one or more additives,
components, integers or steps; its use is not intended to
exclude other additives, components, integers or steps.
0043. The term “stimulating is intended to mean the
transmitting of any energy signal generated by a stimulation
device. Such as an electrical stimulator, to the brain of a

Subject for the purpose of influencing any function or
physiological state of the Subjects brain that is at least one
part of a pathway of pain; or for the purpose of influencing
at least one neurotransmitter associated with pain.
0044) The term “stimulation signal' is intended to mean
any energy signal used in the process of stimulating a tissue
Such as a brain. Other terms used to refer to Such a signal
may include but are not limited to "cranial neurostimula
tion”, “cortical stimulation”, “neuromodulation' and “neu
rostimulation'.

0045. The term “nociceptive pain' is intended to mean
any pain arising from Stimulation of peripheral nerve end
ings.
0046. The term “conductor” is intended to include any
electrical conduction pathway apparatus, such as electrical
leads comprising wires, between an apparatus for providing
electrical stimulation and a tissue to be stimulated. The term

“conductor also includes an electrode or any other termi
nating feature at the end of a conduction pathway apparatus
configured to interface to the tissue to be stimulated.
0047. The term “waveshape' is intended to mean an
electrical signal waveform that may be approximated by an
amplitude envelope resulting from the peaks of an amplitude
modulated pulse train.
0048. The term “analgesia’ is intended to mean any
reduction or elimination in the amount, intensity, duration,
location, form of, or perception of pain.
0049. The term “rest' is intended to mean periods of time
which are part of therapy and in which a patient is in a state
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of preparedness to receive an electrical stimulation signal,
but no signal is actually being delivered to the patient.
0050. The electrical stimulation signal forms taught
herein have been studied in clinical trials involving patients
with fibromyalgia. Clinical data arising from these studies
have demonstrated symptom improvement and evidence
that central nervous system pain processing mechanisms are
modified. Thus, the approach may hold promise for the
treatment of numerous chronic pain states where abnormal
central pain processing mechanisms are involved.
0051. A method is taught for treating a neurological
condition in a patient. Such neurological conditions may
include, but are not limited to, fibromyalgia, hyperalgesia,
central pain, central sensitivity, chronic pain, abnormal brain
network connectivity, neuropathic pain, central pain arising
from chronic osteoarthritis, central pain arising from chronic
back pain, chronic headache, migraine headache or depres
S1O.

0052. The method may include the step of applying an
electrical stimulation signal from conductors to the patients
head at a stimulation application site. The electrical stimu
lation signal may include a tissue transmission component
and a therapeutic component. The method may also include
the step of sequencing the electrical stimulation signal in
bursts. One Such sequence may include at least two burst
periods with at least one rest period in between each pair of
bursts in which no stimulation is provided. In the method,
the electrical stimulation signal may be subthreshold for
detection by the patient. Further, the tissue transmission
component may include a pulse train that has pulse frequen
cies Sufficient to reduce tissue impedance between the con
ductors and the patient’s brain. In one embodiment, the
pulse train amplitude may have a minimum value of 0 Volts
and a maximum value of 1 volt. In another embodiment, the

pulse train amplitude may have a maximum value of 0.2
Volts. In another embodiment, the pulse train frequency is
between 10,000 Hz and 20,000 Hz. In another embodiment,

the pulse train frequency is approximately 15,000 Hz. The
pulse train may also be monopolar.
0053. Further to the method, the pulse train may be pulse
width modulated to create a variable duty cycle of on time
and off time. In one embodiment, the pulse train duty cycle
may be between 20% and 60%. In another embodiment, the
pulse train duty cycle may be approximately 37.5%. Further
still, the pulse train may be amplitude modulated to create a
waveshape which may include an amplitude envelope. Such
waveshapes may include those that are formed to create a
therapeutic component. In one embodiment, the amplitude
envelope may form a rectangular wave. In another embodi
ment, the amplitude envelope may form a sinusoidal wave.
In another embodiment, the amplitude envelope may form a
composite of multiple sinusoidal waves. In one embodi
ment, the waveshape may have a frequency between 1 HZ
and 30 Hz. In another embodiment, the waveshape may have
a frequency between 7 Hz and 12 Hz.
0054. In another embodiment, the waveshape is a rect
angular wave with frequencies ranging from 7 Hz to 12 HZ
as a function of time. In another embodiment, multiple
sinusoidal waves may have individual frequencies between
1 Hz and 30 Hz. Further to the method, the frequency of the
waveshape may change as a function of stimulation delivery
time.

0055. In one embodiment of the method, a pulse train
may have amplitude with minimum value of 0 volts and
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maximum value of 0.2 volts, a frequency of approximately
15,000 Hz, and a duty cycle of approximately 37.5%.
0056 Further to the method, stimulation may be applied
in bursts with periods of time ranging from 1 second to 5
minutes. In one embodiment, each burst period may range in
time from 30 seconds to 2 minutes. Further still, each rest

period may range in time from 1 second to 5 minutes. In one
embodiment, each rest period may be 60 seconds.
0057. Further still to the method, the patient’s electroen
cephalogram (EEG) signal may be measured, including
times when EEG may be measured during a rest period. In
one embodiment, the EEG may be measured at the stimu
lation application site. In another embodiment, the patients
EEG signal may be measured during a period of rest prior to
a first burst of stimulation signal. In an embodiment, Such
periods of rest prior to a first burst may range in time from
1 second to 5 minutes. In another embodiment, such period
of rest prior to a first burst may be 3 minutes.
0058. Further still to the method, the patient's EEG signal
may be measured during a period of rest after a final burst
of stimulation signal. In an embodiment, Such periods of rest
after a final burst may range in time from 1 second to 5
minutes. In another embodiment, such period of rest after a
final burst may be 3 minutes.
0059. Further still to the method, the sequencing step
may include a burst and rest time sequence consisting of a
first three minute period of rest; then applying a first burst of
the electrical stimulation signal for 30 seconds; then after
applying the first burst, ceasing application of the electrical
stimulation signal for a second period of rest lasting 60
seconds; then after the second period of rest, applying a
second burst of the electrical stimulation signal for 60
seconds; then after applying the second burst, ceasing appli
cation of the electrical stimulation signal for a third period
of rest lasting 60 seconds; then after the third period of rest,
applying a third burst of the electrical stimulation signal for
90 seconds; and then after applying the third burst, ceasing
application of the electrical stimulation signal for a fourth
period of rest lasting three minutes. In the embodiments, the
stimulation burst may include a pulse train of pulses having
amplitude with a minimum value of 0 Volts, a maximum
value of 0.2 volts, a frequency of approximately 15,000 Hz
and a duty cycle of approximately 37.5%. Further, the
stimulation signal burst maybe amplitude modulated to form
rectangular waveshapes, with the waveshapes having fre
quencies Sweeping from 7 Hz to 12 HZ over approximately
equal periods of time during the burst.
0060. Further still to the method, the applying step may
include the step of placing conductors to create a current
pathway through at least one portion of the patient’s brain.
Such portions of a brain may be selected from a group
consisting of, but not limited to, the parietal lobes, Soma
tosensory cortex, thalamus, prefrontal cortex, primary motor
cortex, secondary motor cortex, insula or default mode
network. In one embodiment, the conductors may be placed
proximate to the portion of the brain to be stimulated. In
another embodiment, a first conductor may be placed proxi
mate to the parietal lobes along the median plane, and a
second conductor may be placed proximate to the right ear.
In another embodiment, a first conductor may be placed
proximate to International 10-20 site PZ, and a second
conductor may be placed proximate to the right ear lobe. In
another embodiment, the conductors may be noninvasive.
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0061 The method may be further realized by performing
the applying and sequencing steps repeatedly over a period
of time. In one embodiment, the applying and sequencing
steps may be performed at least once a day, with at least one
day transpiring between applications. In another embodi
ment, the applying and sequencing steps may be performed
twice in a calendar week, with two days transpiring between
applications. In another embodiment, the applying and
sequencing steps may be performed repeatedly over a period
ranging from 8 to 24 consecutive weeks. In another embodi
ment, the applying and sequencing steps may be performed
repeatedly over a period of 12 consecutive weeks. In another
embodiment, the applying and sequencing steps may be
performed 24 times over the period of time. In another
embodiment, the applying and sequencing steps may be
performed additional times to further treat the neurological
condition and achieve more satisfactory alleviation of symp
tOmS.

0062. A method is taught for treating a neurological
condition in a patient. Such neurological conditions may
include, but are not limited to, fibromyalgia, hyperalgesia,
central pain, central sensitivity, chronic pain, abnormal brain
network connectivity, neuropathic pain, central pain arising
from chronic osteoarthritis, central pain arising from chronic
back pain, chronic headache, migraine headache or depres
Sion. The method may include placing a first conductor on
the patient’s head proximate to International 10-20 site PZ
and placing a second conductor proximate to the patients
right ear lobe; then applying an electrical stimulation signal
between the first and second conductors, where the electrical

stimulation signal may include a tissue transmission com
ponent which may further include a monopolar pulse train of
frequency sufficient to reduce tissue impedance between the
conductors and the patient's brain, and where the pulse train
amplitude may have a minimum value of 0 Volts, a maxi
mum value of 0.2 volts, a frequency of approximately
15,000 Hz and a duty cycle of approximately 37.5%, and
where the pulse train may be amplitude modulated to form
a rectangular waveshape with frequencies ranging from 7 HZ
to 12 HZ, as a function of time; then sequencing the appli
cation of the electrical stimulation signal in a burst and rest
time sequence consisting of a first three minute period of
rest; and then after the first period of rest, applying a first
burst of the electrical stimulation signal for 30 seconds, with
frequencies sweeping from 7 Hz to 12 Hz over approxi
mately equal periods of time during the burst; and then after
applying the first burst, ceasing application of the electrical
stimulation signal for a second period of rest lasting 60
seconds; and then after the second period of rest, applying
a second burst of the electrical stimulation signal for 60
seconds, with frequencies sweeping from 7 Hz to 12 Hz over
approximately equal periods of time during the burst; and
then after applying the second burst, ceasing application of
the electrical stimulation signal for a third period of rest
lasting 60 seconds; and then after the third period of rest,
applying a third burst of the electrical stimulation signal for
90 seconds, with frequencies sweeping from 7 Hz to 12 HZ
over approximately equal periods of time during the burst;
and then after applying the third burst, ceasing application of
the electrical stimulation signal for a fourth period of rest
lasting three minutes; and then performing the placing,
applying and sequencing steps twice in a calendar week,
with at least one day transpiring between treatment appli
cations, over a period of 12 consecutive weeks.
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0063 A method is taught for treating a neurological
condition in a patient. Such neurological conditions may
include, but are not limited to, fibromyalgia, central sensi
tivity, central pain, abnormal neural network connectivity,
complex regional pain syndrome, phantom pain, irritable
bowel syndrome, temporomandibular disorder, myofascial
pain syndrome, regional Soft-tissue pain syndrome, neuro
pathic pain, osteoarthritis, back pain, post-operative pain,
depression, tension-type headaches or migraine headaches.
0064. The method may include the step of applying an
electrical stimulation from conductors to the patient’s head
at a stimulation application site, and in which the electrical
stimulation may include a composite electrical signal which
may further include at least one signal form configured to
provide long-term treatment of the neurological condition
and at least one signal form configured to provide analgesia
for short-term pain relief.
0065. In one embodiment, the at least one signal form
configured to provide long-term treatment of the neurologi
cal condition and the at least one signal form configured to
provide analgesia for short-term pain relief may be applied
simultaneously during a treatment application. In another
embodiment, the at least one signal form configured to
provide long-term treatment of the neurological condition
and the at least one signal form configured to provide
analgesia for short-term pain relief may be applied at
alternating times during a treatment application.
0066. In one embodiment, the at least one signal form
configured to provide long-term treatment of the neurologi
cal condition may include an electrical signal configured to
treat an abnormal brain condition associated with the neu

rological condition. In another embodiment, the at least one
signal form configured to provide analgesia for short-term
pain relief may include an electrical signal configured to
stimulate modulation of one or more neurotransmitters asso

ciated with analgesia. Further to the embodiment, the modu
lation may be selected from a group consisting of, but not
limited to, the release, expression, uptake, increased pro
duction, reduced production, inhibition or elimination of
neurotransmitters. Further to the embodiment, the neu

rotransmitters may be selected from a group consisting of
but not limited to, serotonin, norepinephrine, glutamate,
N-Methyl-D-aspartic acid, Substance P, gama-aminobutyric
acid, various nucleotides or dopamine.
0067. In an embodiment of the method, the at least one
signal form configured to provide long-term treatment of the
neurological condition may include a tissue transmission
component and a therapeutic component. Further to the
embodiment, the tissue transmission component may
include a pulse train of frequency Sufficient to reduce tissue
impedance between the conductors and the patient’s brain.
Further still, the pulse train amplitude may have a minimum
value of 0 volts and a maximum value of 1 volt. In another

embodiment, the pulse train amplitude may have a maxi
mum value of 0.2 volts. In one embodiment, the pulse train
frequency may be between 10,000 Hz and 20,000 Hz. In
another embodiment, the pulse train frequency may be
approximately 15,000 Hz. In the embodiments, the pulse
train may be monopolar. Further to the embodiments, the
electrical stimulation may be subthreshold for detection by
the patient.
0068. Further to the method, the pulse train may be pulse
width modulated to create a variable duty cycle of on time
and off time. In one embodiment, the pulse train duty cycle
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may be between 20% and 60%. In another embodiment, the
pulse train duty cycle may be approximately 37.5%. Further
still to the method, the pulse train may be amplitude modu
lated to create a waveshape which may include an amplitude
envelope. In one embodiment, the waveshape may form a
therapeutic component. In another embodiment, the ampli
tude envelope may form a rectangular wave. In another
embodiment, the amplitude envelope may form a sinusoidal
wave. In another embodiment, the amplitude envelope may
form a composite of multiple sinusoidal waves. In one
embodiment, the waveshape may have a frequency between
1 Hz and 30 Hz. In another embodiment, the waveshape may
have a frequency between 7 Hz and 12 Hz. In another
embodiment, the waveshape is a rectangular wave with
frequencies ranging from 7 Hz to 12 HZ, as a function of
time. In another embodiment, multiple sinusoidal waves
may have individual frequencies between 1 Hz, and 30 Hz.
Further to the method, the frequency of the waveshape may
change as a function of Stimulation delivery time.
0069. In one embodiment of the method, a pulse train
may have amplitude with minimum value of 0 volts and
maximum value of 0.2 volts, a frequency of approximately
15,000 Hz, and a duty cycle of approximately 37.5%.
0070 Further to the method, stimulation may be applied
in bursts with periods of time ranging from 1 second to 5
minutes. In one embodiment, each burst period may range in
time from 30 seconds to 2 minutes. Further still, each rest

period may range in time from 1 second to 5 minutes. In one
embodiment, each rest period may be 60 seconds.
0071. Further still, the electrical stimulation may include
a sequencing step in which an electrical signal is applied in
bursts for at least two burst periods with at least one rest
period which may include no stimulation in between each
pair of bursts. In one embodiment, each burst period may
range in time from 1 second to 5 minutes. In another
embodiment, each burst period may range in time from 30
seconds to 2 minutes. In one embodiment, each rest period
may range in time from 1 second to 5 minutes. In another
embodiment, each rest period may be 60 seconds.
0072 Further still to the method, the patient’s electroen
cephalogram (EEG) signal may be measured, including
times when EEG may be measured during a rest period. In
one embodiment, the EEG may be measured at the stimu
lation application site. In another embodiment, the patients
EEG signal may be measured during a period of rest prior to
a first burst of stimulation signal. In an embodiment, Such
periods of rest prior to a first burst may range in time from
1 second to 5 minutes. In another embodiment, such period
of rest prior to a first burst may be 3 minutes.
0073. Further still to the method, the patient's EEG signal
may be measured during a period of rest after a final burst
of stimulation signal. In an embodiment, such periods of rest
after a final burst may range in time from 1 second to 5
minutes. In another embodiment, such period of rest after a
final burst may be 3 minutes.
0074. Further still to the method, the sequencing step
may include a burst and rest time sequence consisting of a
first three minute period of rest; then applying a first burst of
the electrical stimulation signal for 30 seconds; then after
applying the first burst, ceasing application of the electrical
stimulation signal for a second period of rest lasting 60
seconds; then after the second period of rest, applying a
second burst of the electrical stimulation signal for 60
seconds; then after applying the second burst, ceasing appli
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cation of the electrical stimulation signal for a third period
of rest lasting 60 seconds; then after the third period of rest,
applying a third burst of the electrical stimulation signal for
90 seconds; and then after applying the third burst, ceasing
application of the electrical stimulation signal for a fourth
period of rest lasting three minutes. In the embodiments, the
stimulation burst may include a pulse train of pulses having
amplitude with a minimum value of 0 Volts, a maximum
value of 0.2 volts, a frequency of approximately 15,000 Hz
and a duty cycle of approximately 37.5%. Further, the
stimulation signal burst maybe amplitude modulated to form
rectangular waveshapes, with the waveshapes having fre
quencies Sweeping from 7 Hz to 12 HZ over approximately
equal periods of time during the burst.
0075. Further to the method, the at least one signal form
configured to provide analgesia for short-term pain relief
may include a periodic signal. In one embodiment, the
periodic signal may be a pulse train. In another embodiment,
the periodic signal may be a sinusoidal waveform. In another
embodiment, the periodic signal may have frequencies
between 1 Hz and 300 Hz. In another embodiment, the

periodic signal may have frequencies between 50 Hz, and
150 Hz. In another embodiment, the periodic signal may
have a frequency of approximately 60 Hz. In another
embodiment, the periodic signal may have a frequency of
approximately 120 Hz. In one embodiment, the periodic
signal may have amplitudes between -10 volts and +10
Volts. In another embodiment, the periodic signal may have
a minimum amplitude of -1 volts and maximum amplitude
of +1 volt.

0076 Further to the method, the at least one signal form
configured to provide analgesia for short-term pain relief
may be applied during periods of rest time before or after
bursts of at least one signal form configured to provide
long-term treatment of a neurological condition. Further
still, the at least one signal form configured to provide
analgesia for short-term pain relief may include a direct
current (DC) signal.
0077. Further still to the method, the applying step may
include the step of placing conductors to create a current
pathway through at least one portion of the patient’s brain.
Such portions of a brain may be selected from a group
consisting of, but not limited to, the parietal lobes, Soma
tosensory cortex, thalamus, prefrontal cortex, primary motor
cortex, secondary motor cortex, insula or default mode
network. In one embodiment, the conductors may be placed
proximate to the portion of the brain to be stimulated. In
another embodiment, a first conductor may be placed proxi
mate to the parietal lobes along the median plane, and a
second conductor may be placed proximate to the right ear.
In another embodiment, a first conductor may be placed
proximate to International 10-20 site PZ, and a second
conductor may be placed proximate to the right ear lobe. In
another embodiment, the conductors may be noninvasive.
0078. The method may be further realized by performing
the applying and sequencing steps repeatedly over a period
of time. In one embodiment, the applying and sequencing
steps may be performed at least once a day, with at least one
day transpiring between applications. In another embodi
ment, the applying and sequencing steps may be performed
twice in a calendar week, with two days transpiring between
applications. In another embodiment, the applying and
sequencing steps may be performed repeatedly over a period
ranging from 8 to 24 consecutive weeks. In another embodi
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ment, the applying and sequencing steps may be performed
repeatedly over a period of 12 consecutive weeks. In another
embodiment, the applying and sequencing steps may be
performed 24 times over the period of time. In another
embodiment, the applying and sequencing steps may be
performed additional times to further treat the neurological
condition and achieve more satisfactory alleviation of symp
tOmS.

007.9 Further to the method, the applying step may
include applying electrical stimulation through conductors
that create at least a first current pathway through at least a
first portion of the patient’s brain for providing long-term
treatment of the neurological condition, and at least a second
current pathway through at least a second portion of the
patient’s brain for providing analgesia for short-term pain
relief. In one embodiment, the conductors may include at
least two electrical leads placed proximate to the portion of
the patient’s brain to be stimulated. In another embodiment,
the conductors may be noninvasive.
0080 A method is taught for treating a neurological
condition in a patient. Such neurological conditions may
include, but are not limited to, fibromyalgia, hyperalgesia,
central pain, central sensitivity, chronic pain, abnormal brain
network connectivity, neuropathic pain, central pain arising
from chronic osteoarthritis, central pain arising from chronic
back pain, chronic headache, migraine headache or depres
Sion. The method may include placing a first electrical lead
on the patients head proximate to International 10-20 site
PZ and placing a second electrical lead proximate to the
patient’s right ear lobe; and then applying a composite
electrical stimulation signal which may include a signal
configured to provide long-term treatment of the neurologi
cal condition and a signal configured to provide analgesia
for short-term pain relief, where the signal configured to
provide analgesia for short-term pain relief may include a
pulse train of both 60 Hz positive pulses and 60 Hz, negative
pulses, where the positive pulses may have a minimum
amplitude of 0 volts and a maximum amplitude of 0.5 volts,
where the negative pulses may have a maximum amplitude
of 0 volts and a minimum amplitude of -0.5 volts, where the
positive and negative pulses may alternate in time and may
be equally spaced in time, where the signal to provide
long-term treatment of the neurological condition may
include a monopolar pulse train of frequency Sufficient to
reduce tissue impedance, where the pulse train amplitude
may have a minimum value of 0 Volts, a maximum value of
0.2 volts, a frequency of approximately 15,000 Hz and a
duty cycle of approximately 37.5%, and where the pulse
train may be amplitude modulated to form a rectangular
waveshape with frequencies which ranging from 7 Hz to 12
HZ as a function of time; and then sequencing application of
the electrical stimulation signal in a burst and rest time
sequence that may consist of a first burst which may include
the signal configured to provide analgesia for short-term
pain relief, lasting three minutes, then a second burst which
may include the signal configured to provide long-term
treatment of the neurological condition, lasting 30 seconds,
with frequencies sweeping from 7 Hz to 12 Hz over approxi
mately equal periods of time during the burst, and then a
third burst which may include the signal configured to
provide analgesia for short-term pain relief, lasting 60
seconds, and then a fourth burst which may include the
signal configured to provide long-term treatment of the
neurological condition, lasting 60 seconds, with frequencies
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sweeping from 7 Hz to 12 Hz over approximately equal
periods of time during the burst, and then a fifth burst which
may include the signal configured to provide analgesia for
short-term pain relief, lasting 60 seconds, and then a sixth
burst which may include the signal configured to provide
long-term treatment of the neurological condition, lasting 90
seconds, with frequencies sweeping from 7 Hz to 12 Hz over
approximately equal periods of time during the burst; and
then a seventh burst which may include the signal config
ured to provide analgesia for short-term pain relief, lasting
three minutes; and then conducting the electrical stimulation
along a current pathway which may be created between the
first electrical lead placed proximate to International 10-20
site PZ, and the second electrical lead placed proximate to
the right earlobe; and then performing the placing, applying
and sequencing steps twice in a calendar week, with at least
one day transpiring between treatment applications, over a
period of 12 consecutive weeks.
I0081. An electrical stimulation apparatus is taught which
may include an electrical signal generator adapted to provide
an electrical signal form configured to provide long-term
treatment of a neurological condition and to provide an
electrical signal form configured to provide analgesia for
short-term pain relief. In one embodiment, the electrical
signal generator may further include at least one microcon
troller configured to generate composite signal waveforms
and coupled to at least one signal conditioning circuit
configured to transform the composite signal waveforms
into stimulation signals. Further to the embodiment, the at
least one signal conditioning circuit may include an ampli
fier circuit.

0082 In another embodiment, the electrical stimulation
apparatus may further include any one or more circuit
elements selected from the group of circuit elements con
sisting of, but not limited to, an EEG amplifier configured to
measure EEG signals, a filter circuit configured to reduce
electrical noise in EEG signals, an isolation amplifier con
figured to protect human Subjects, an analog-to-digital inter
face configured to convert analog EEG signals to digital
signals, and an isolated power Supply configured to provide
circuit power and human Subject protection.
I0083. Further still, an embodiment of the apparatus may
further include at least two electrical leads for providing a
composite stimulation signal current pathway between the
electrical signal generator and a tissue to be stimulated. In
another embodiment, the apparatus may further include a
user interface, which may further include a software graphic
user interface which provides user guidance for providing a
composite stimulation signal.
BRIEF DESCRIPTION OF THE DRAWINGS

0084. The novel features of the invention are set forth
with particularity in the claims that follow. A better under
standing of the features and advantages of the present
invention will be obtained by reference to the following
detailed description that sets forth illustrative embodiments,
in which the principles of the invention are utilized, and the
accompanying drawings of which:
I0085 FIG. 1 shows an apparatus for providing electrical
stimulation according to an embodiment of the invention.
I0086 FIG. 2 shows an example composite stimulation
signal featuring one signal form configured for providing
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long-term treatment of a neurological condition and a sec
ond signal form configured for providing analgesia for
short-term pain relief.
0087 FIG. 3 shows a block diagram of a composite
electrical signal generator apparatus according to an
embodiment of the invention.

0088 FIG. 4 shows a block diagram of a composite
electrical signal generator apparatus to manage timing of the
therapy application according to an embodiment of the
invention.
DETAILED DESCRIPTION

0089. While the use of electrical stimulation for thera
peutic purposes has been taught through numerous examples
in the art, the methods and apparatuses described herein
provide several advantages and improvements over previ
ously disclosed matter.
0090 Disclosed herein is an electrical stimulation system
involving forms of electrical stimulation signals and treat
ment delivery strategies that have been shown in clinical
research trials to provide therapeutic advantages and lasting
results in persons suffering from fibromyalgia and similar
pain conditions involving central pain.
0091. A key element of the electrical stimulation methods
taught herein is the utilization of stimulation signal forms
that include (1) a transmission component configured to
enhance the ability of the signal to transmit through tissues
to be stimulated, and to do so in a way that reduces
attenuation due to tissue impedance; and (2) a therapeutic
component configured to treat mechanisms involved in
central pain, such as central sensitivity and abnormal neural
network connectivity in the brain. In this invention, the
therapeutic signal component may be configured to treat
nociceptive pain or provide analgesia. Alternately, the thera
peutic signal component may be configured to reduce aber
rant brain function mechanisms such as those that process
pain signals in ways that cause abnormal perception of pain.
In other words, the methods taught herein target abnormal
pain processing mechanisms, but may also treat nociceptive
generators of pain or block pain signals ascending from
peripheral nerves.
0092 Such signal components configured to enhance
signal transmission include the use of a pulse train of
frequency high enough to reduce the electrical admittivity of
intervening tissues between a conductor and the brain. In
one embodiment, the pulse train is monopolar so as to
deliver a positive net charge to the patient. It may also be
pulse width modulated in a way that advantageously creates
a variable duty cycle. This is done to provide control of the
time averaged power delivered by the pulse train signal.
0093. The method is further realized when the pulse train
is amplitude modulated to create a waveshape comprising an
amplitude envelope approximately following the peak val
ues of the amplitude modulated pulses. The waveshape is
created in a way that the amplitude envelope forms another
periodic signal having at least one frequency lower than the
frequency of the pulse train. Such periodic signals may be
realized through any waveform, Such as a rectangular wave,
a sinusoidal wave, or a composite of multiple sinusoidal
waves. The frequencies of the waveshape may be fixed, or
they may change over time as the stimulation signal is being
delivered. Advantages of changing frequencies over time
may include the ability to provide (1) a broader range of
frequency-dependent stimulation benefits in a single therapy
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application, and (2) a sequential adjustment of stimulation
frequency that may prevent overstimulation of the brain at
any particular frequency.
0094. The lower frequency waveshape provides the
stimulation signals therapeutic component configured to
treat mechanisms involved in central pain, such as central
sensitivity and abnormal neural network connectivity in the
brain. In combination, the signal component configured to
enhance signal transmission and the therapeutic lower fre
quency waveshape provides a stimulation signal that can be
effectively transmitted through tissues with lower driving
Voltages. The advantages of this include greater safety in the
stimulation signal, and the ability to provide therapeutic
electrical stimulation with signals that are subthreshold for
detection by a patient being stimulated. In treating patients
who are suffering from enhanced pain processing, and are
therefore experiencing allodynia and/or hyperalgesia, the
ability to stimulate without the signal itself causing pain or
any negative sensation is a significant advantage.
0.095 The signal method may further include a signal
component that is configured to provide analgesia for short
term pain relief. While a signal featuring components to
reduce aberrant brain function mechanisms that process pain
signals in ways that cause an abnormal perception of pain
has long-term therapeutic utility, actual pain relief experi
enced by the patient may not be immediate. Thus, in some
embodiments the method uses additional signal components
that may, among other things, modulate neurotransmitters in
the body to cause analgesia and short-term pain relief.
0096 Such signals configured to provide analgesia may
include a DC signal or a periodic signal Such as pulse trains
or sinusoidal waveforms. Such periodic signals may have
frequencies between 1 Hz and 300 Hz, which is a range of
frequencies sometimes known as the “physiologic stimula
tion range'. Other frequencies may be selected to stimulate
certain neurotransmitters. For example, it is known that
frequencies in the range of 50-150 Hz, may stimulate the
release of the pain mediating neurotransmitters dopamine,
serotonin and norepinephrine. Such periodic signals may
also have both positive and negative amplitudes ranges, such
as for example between -1 volt and +1 volt.
0097. The method is further realized when the electrical
stimulation signals are delivered in a therapeutic setting,
using repeat applications and over a period of time. The
advantages of repeat applications over a period of time
include the provision of therapy that modulates the abnormal
pain processing mechanisms associated with fibromyalgia
and other neurological conditions involving central pain,
reinforces normal pain processing mechanisms, and there
fore creates a lasting therapeutic benefit.
0098. Further to the method, the repeat applications of
therapy involve signal deliveries in bursts typically lasting
anywhere from a few seconds to several minutes. Before,
after and in between these bursts, the method involves

periods of therapeutic rest in which the patient remains in a
state for receiving stimulation, but no stimulation signal is
actually delivered. Such state for receiving stimulation may
include the patient being physically connected to conductors
of an electrical stimulation apparatus, sitting still in a clinical
environment during which time their eyes are closed and
they are purposefully told to relax.
0099. During such rest periods, the patient merely spends
time in a state of relaxation and disengagement from general
attentiveness to their Surroundings. Providing such rest
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periods may be therapeutically advantageous in that the
mechanisms associated with abnormal pain processing, for
example hyperconnectivity in brain networks, may diminish
or mitigate when a patient is in Such state. When the
stimulation bursts are Subsequently applied, the stimulation
may reinforce states Such as a reduced connective state, and
therefore reinforce the therapeutic benefit.
0100 Further still to the method, the therapy applications
may be provided over a period of several days per week and
several weeks per a course of therapy. The advantage of Such
approach is again conceived to provide long-term therapeu
tic benefit. The method also anticipates a therapeutic advan
tage of providing at least one day in between therapy
applications, during which time the patient will receive no
stimulation therapy.
0101. Further still to the method, the patient’s electroen
cephalogram (EEG) signal may be measured at times con
sistent with the therapy application. In one embodiment,
EEG may be measured during periods of rest. In another
embodiment, EEG may be measured at the electrical stimu
lation signal application site. In yet another embodiment,
EEG may be measured at a number of additional sites on the
Scalp. The uses for EEG measurement at the signal appli
cation site include means of assuring the integrity of elec
trical contact between conductors and the patient, and thus
assuring quality stimulation signal delivery. The uses for
EEG measurement at additional sites on the scalp include
providing a means for assessing brain neural network con
nectivity before, during and after stimulation signal appli
cation, the benefits of which may include providing indica
tion of the levels and characteristics of at least one parameter
of abnormal pain processing mechanisms in the brain.
0102. With reference to FIG. 1, the method may be
practiced by using an apparatus 1 configured to generate
electrical stimulation signals, and in particular the kinds of
composite electrical stimulation signals disclosed herein. In
one embodiment. Such apparatus 1 includes conductors 2
that are adapted to rest on the patient’s head 3. Therapy
begins after a patient 4 presents in clinic and is taken to a
clinical setting, which may include a quiet room in which
lighting can be reduced, and in which the room contains a
comfortable chair for the patient to use during therapy and
which has adequate Support for the patient's head 3 and
neck. The conductors 2 are used to establish electrical

contact between the apparatus 1 and the patient’s head 3.
Such contact may be enhanced by using cutaneous elec
trodes 5 and electrically conductive gel, both of which are
well known in the art of electrophysiological measurements.
0103) The conductors 2 are placed in a way such that the
stimulation signal will pass through or proximate brain
tissues to be stimulated. In various embodiments, such brain

tissues may include, but are not limited to, the parietal lobes,
Somatosensory cortex, thalamus, prefrontal cortex, primary
motor cortex, secondary motor cortex, insula or default
mode network.

0104. Once electrical contact is established, the rooms
lighting is typically reduced and the patient 4 is encouraged
to close their eyes and relax. At that point, a clinical
professional causes the apparatus 1 to start the therapy
application, which starts a timer internal to the apparatus 1.
The therapy application, using burst and rest sequences as
described herein, is then applied according to the timing of
the apparatus 1.
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0105. With specific reference to the embodiments, a
method is provided for treating fibromyalgia, which is a
chronic full body pain condition featuring centralized pain,
and in many cases, underlying conditions that also cause
nociceptive pain. A method is also provided for treating
other central pain related neurological conditions, which
include but are not limited to hyperalgesia, central pain,
central sensitivity, chronic pain, abnormal brain network
connectivity, neuropathic pain, central pain arising from
chronic osteoarthritis, central pain arising from chronic back
pain, chronic headache, migraine headache or depression.
All of these conditions either feature or are believed to be

causally related to centralized pain, which is further believed
to be related to central sensitivity and abnormal neural
network connectivity in pain processing areas of the brain.
0106. The method includes the use of an electrical stimu
lation signal configured to reduce tissue impedance and
deliver stimulation to brain tissues without being perceived
by a patient 4 who is receiving the stimulation. In a preferred
embodiment, the electrical stimulation signal comprises a
tissue transmission signal further comprising a pulse train of
frequency Sufficient to reduce tissue impedance. Further, the
individual pulses in the pulse train are pulse width modu
lated to create a variable duty cycle of on time and off time.
Such pulse width modulation is conceived to control the
time-averaged power delivered over an individual period of
the pulses in the pulse train. Further still, the electrical
stimulation signal comprises a therapeutic signal created by
amplitude modulating the pulse train of the tissue transmis
sion signal to create a waveshape comprising an amplitude
envelope. In some embodiments, the waveshape forms a
stimulation signal of at least one lower frequency compared
with the frequency of the pulse train, and it is this lower
frequency signal that acts as the therapeutic signal.
0107. In one embodiment, the pulse train amplitudes and
frequencies are chosen to be subthreshold for detection by a
person being stimulated. In some instances of prior art,
electrical stimulation methods are taught that teach avoid
ance of amplitudes and frequencies that are within the
perceptible physiological stimulation range, that is, approxi
mately between 1-300 Hertz (Hz), so as to prevent noxious
sensations in a person receiving stimulation. However, the
present invention teaches the combination of high frequency
and low amplitude signals that are capable of providing
stimulation within said physiological stimulation range that
is not detected by a person receiving stimulation and still
causes a therapeutic effect.
0.108 Such combinations of signal amplitudes and fre
quencies, in the embodiment, may include a pulse train with
amplitude at a minimum value of 0 Volts and a maximum
value of 1 volt. In the preferred embodiment, the pulse train
amplitude has a maximum value of 0.2 volts. Such combi
nations may also include a pulse train with frequencies
between 10,000 Hz and 20,000 Hz. In the preferred embodi
ment, the pulse train frequency is approximately 15,000 Hz.
This range of frequencies has been shown in tissue modeling
studies to effectively overcome the impedances of the tissues
of the head 3, thus allowing a stimulation signal applied
noninvasively to pass through outer tissues such as the scalp
and skull with less attenuation.

0109 Further to the embodiment, the pulse train may be
of any form, Such as a monopolar waveform. Further still,
the pulse train duty cycle may be between 20% and 60%.
These duty cycles are anticipated to provide time-averaged
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power levels that are effective. In one exemplary embodi
ment, the pulse train duty cycle is approximately 37.5%.
0110. Further still to the embodiments, the amplitude
envelope formed by amplitude modulating the pulse train
may form any waveshape. In one embodiment, the ampli
tude envelope may form a rectangular wave. Such rectan
gular waveshape may be advantageous as it has shown
efficacy in clinical studies for treating pain in fibromyalgia.
In another embodiment, the amplitude envelope forms a
sinusoidal wave. In yet another embodiment, the amplitude
envelope forms a composite of multiple sinusoidal waves.
Such composite of multiple sinusoidal waves may be advan
tageous in that multiple lower stimulating frequencies are
represented by a single waveshape.
0111. In all embodiments, the waveshape is configured as
a periodic waveform of frequencies sufficient to cause
therapeutic electrical stimulation. In one embodiment, the
waveshape has a frequency between 1 Hz and 30 Hz. This
frequency range may also be used in embodiments involving
multiple sinusoidal waves. This frequency range matches a
range of frequencies commonly found in EEG signals in the
human brain. In one embodiment, the waveshape has a
frequency between 7 Hz and 12 Hz. This range provides
stimulation in a range of frequencies commonly found in
EEG signals in the human brain and representative of
normal, alert conditions. In all embodiments, the frequency
of the waveshape may be configured to change as a function
of stimulation delivery time.
0112. In one embodiment, a specific electrical stimulation
method for treating fibromyalgia or other central pain related
neurological conditions uses a pulse train which has a
minimum amplitude value of 0 Volts, a maximum value of
0.2 volts, a frequency of approximately 15,000 Hz and a
duty cycle of approximately 37.5%. In the embodiment, the
waveshape is a rectangular wave with frequencies ranging
from 7 Hz to 12 Hz, as a function of time. Further to the

embodiment, the electrical stimulation signal is applied in
sequences of bursts for at least two periods of time with at
least one period of rest time comprising no stimulation in
between each signal application. In one embodiment, EEG
signal may be measured as part of the method. In one
embodiment, EEG may be measured at the stimulation
application site during the periods of rest. The measurement
of EEG would be apparent to one ordinarily skilled in the art.
Further to the embodiment, the bursts of stimulation signal
may range in time from 1 second to 5 minutes. In another
embodiment, the bursts of Stimulation signal range in time
from 30 seconds to 2 minutes. Further still to the embodi

ment, the periods of rest range in time from 1 second to 5
minutes. In another embodiment, the periods of rest are 60
seconds. Further still to the embodiment, EEG signal is
measured for a period of time prior to a first burst of
stimulation signal, with said period of time prior ranging
from 1 second to 5 minutes. In a preferred embodiment, the
period of time prior to a first burst is 3 minutes. Likewise,
in still another embodiment, EEG signal is measured for a
period of time after a final burst of stimulation signal, with
said period of time prior ranging from 1 second to 5 minutes.
In a preferred embodiment, the period of time after a final
burst is 3 minutes.

0113. In one embodiment, the electrical stimulation com
prises a burst and rest time sequence consisting of a first
three minute period of rest, a first burst of stimulation signal
lasting 30 seconds, a second period of rest lasting 60
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seconds, a second burst of stimulation signal lasting 60
seconds, a third period of rest lasting 60 seconds, a third
burst of stimulation lasting 90 seconds, and a fourth period
of rest lasting three minutes. In an exemplary embodiment,
the stimulation signal burst is a pulse train that is amplitude
modulated to form rectangular waveshapes, with said wave
shapes having frequencies Sweeping from 7 Hz to 12 HZ
over approximately equal periods of time during the burst.
0114. Further to all embodiments of the methods taught
herein, the electrical stimulation signal is conducted along a
current pathway extending through at least one portion of a
brain. In one embodiment, such portions of a brain are
selected from those portions that are involved in central
pain. Such portions of a brain may include, but are not
limited to, the parietal lobes, somatosensory cortex, thala
mus, prefrontal cortex, primary motor cortex, secondary
motor cortex, insula or default mode network. Further to the

embodiment, the method is accomplished by using at least
two electrical leads that are either invasive or noninvasive,

and are placed proximate to the portion of a brain to be
stimulated, such that a current pathway includes said portion
of a brain. In one embodiment, Such current pathway is
provided by placing a first electrical lead proximate to the
parietal lobes along the median plane of a human head3, and
a second electrical lead is placed proximate to the right ear
of the head 3. In another embodiment, another current

pathway is provided by placing a first electrical lead proxi
mate to International 10-20 electrode placement site PZ on a
head 3, and a second electrical lead is placed proximate to
the right ear lobe of the head 3. The placement of electrical
leads and accomplishment of electrical interface is readily
known to those of ordinary skill in the art.
0115 Further to the method, treating fibromyalgia or
other central pain related neurological conditions consists of
treatment applications of the electrical stimulation signal
methods taught herein, wherein the treatment applications
are applied repeatedly over a period of time to cause a
lasting therapeutic effect. In one embodiment, treatment
applications are applied at least once a day, with at least one
day transpiring between treatment applications during which
time no electrical stimulation is applied to the patient 4. In
another embodiment, treatment applications are applied
twice in a calendar week, with two days transpiring between
treatment applications. Further to the embodiment, treat
ment is applied over a range of 8 to 24 weeks. In one
exemplary embodiment, treatment comprises 24 treatment
applications applied over a period of 12 consecutive weeks.
The method is further accomplished when additional treat
ment applications are applied as necessary to further treat
the fibromyalgia and achieve more satisfactory alleviation of
symptoms.

0116. In one embodiment, a method of treating fibro
myalgia or other central pain related neurological conditions
is accomplished using an electrical stimulation signal com
prising a monopolar pulse train of frequency Sufficient to
reduce tissue impedance; wherein the pulse train amplitude
has a minimum value of 0 volts, a maximum value of 0.2

volts, a frequency of approximately 15,000 Hz and a duty
cycle of approximately 37.5%; wherein the pulse train is
amplitude modulated to form a rectangular waveshape with
frequencies ranging from 7 Hz to 12 HZ, as a function of
time; wherein each application of the electrical stimulation
comprises the burst and rest time sequence consisting of a
first three minute period of rest, a first burst of stimulation
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signal lasting 30 seconds with frequencies Sweeping from 7
HZ to 12 HZ over approximately equal periods of time during
the burst, a second period of rest lasting 60 seconds, a
second burst of Stimulation signal lasting 60 seconds with
frequencies sweeping from 7 Hz to 12 Hz over approxi
mately equal periods of time during the burst, a third period
of rest lasting 60 seconds, a third burst of stimulation lasting
90 seconds with frequencies sweeping from 7 Hz to 12 HZ
over approximately equal periods of time during the burst
and a fourth period of rest lasting three minutes; wherein the
electrical stimulation is conducted along a current pathway
created between a first electrical lead placed proximate to
International 10-20 site PZ, and a second electrical lead

placed proximate to the right ear lobe; in which the treatment
applications are applied twice in a calendar week, with two
days transpiring between treatment applications; and in
which the treatment applications are applied over a period of
12 consecutive weeks.

0117. Further to the present invention, and with reference
to FIG. 2, a method of treating a neurological condition is
accomplished by using an electrical stimulation that is a
composite signal 6 made up of multiple electrical signals.
Such composite signal 6 may feature an electrical signal that
has at least one signal form 7 configured to provide long
term treatment of the neurological condition by providing
electrical stimulation that is therapeutic to physiological
mechanisms involved in the neurological condition. An
example of Such physiological mechanisms may include
abnormal brain conditions, such as excessive or insufficient
neural network connectivity, and excessive or insufficient
activity in brain regions associated with the neurological
condition. Such composite 6 may further feature an electri
cal signal that has at least one signal form 8 configured to
provide analgesia for short-term pain relief, whether the pain
is associated with the neurological condition or not.
0118. The advantage of such composite signals 6 is to
provide multiple therapeutic benefits to a person receiving
electrical stimulation. In particular, a person Suffering from
a neurological condition may experience multiple symptoms
including pain. For example, a person Suffering from fibro
myalgia may experience pain, fatigue, stiffness, cognitive
impairment, depression, anxiety, symptoms of irritable
bowel syndrome and abnormal sensitivities. These symp
toms may all be linked to central sensitivity, which may
further be linked to an abnormal brain condition such as

abnormal neural network connectivity, and may therefore be
neurological in nature. A composite signal 6 as taught herein
may include a signal form 7 configured to provide therapy
to the brain mechanisms that are related to the neurological
condition, and thus provide long-term benefit and symptom
relief. The composite signal may also provide an additional
signal form 8 configured to provide symptom relief that is
relatively immediate in comparison. In the method, Such
additional signal form may be configured to provide short
term pain relief, regardless of whether the pain is nocicep
tive or central in nature. An example of Such additional
signal form may be one configured to modulate one or more
neurotransmitters associated with pain or analgesia.
0119 The practice of such composite electrical signals
may be accomplished using any number of methods well
known in the art, such as but not limited to the Superposition
of at least two individual signals. Such methods are known
to a person ordinarily skilled in the art of electrical signal
generation.

0.120. In one embodiment of the method, the at least one
signal form 7 configured to provide long-term treatment of
the neurological condition and the at least one signal form 8
configured to provide analgesia for short-term pain relief
may be applied simultaneously during a treatment applica
tion. In another embodiment, the signal forms may be
applied at alternating times during a treatment application.
I0121 Further to the embodiment, the at least one signal
form 7 configured to provide long-term treatment of the
neurological condition may comprise an electrical signal
configured to treat an abnormal brain condition associated
with the neurological condition, and the at least one signal
form 8 configured to provide analgesia for short-term pain
relief comprises an electrical signal configured to stimulate
modulation of one or more neurotransmitters associated with

analgesia. Such modulation may be selected from a group
consisting of the release, expression, uptake, increased pro
duction, reduced production, inhibition or elimination of
neurotransmitters. Such neurotransmitters may be selected
from a group consisting of but not limited to serotonin,
norepinephrine, glutamate, N-Methyl-D-aspartic acid, Sub
stance P, gama-aminobutyric acid, various nucleotides or
dopamine. Such neurological conditions may consist of but
are not limited to fibromyalgia, central sensitivity, central
pain, abnormal neural network connectivity, complex
regional pain syndrome, phantom pain, irritable bowel syn
drome, temporomandibular disorder, myofascial pain Syn
drome, regional Soft-tissue pain syndrome, neuropathic pain,
osteoarthritis, back pain, post-operative pain, depression,
tension-type headaches or migraine headaches.
0.122 Further to the method, the at least one signal form
7 configured to provide long-term treatment of the neuro
logical condition may comprise an electrical stimulation
signal as taught herein configured to reduce tissue imped
ance and deliver Stimulation to brain tissues without being
perceived by a patient 4 who is receiving the stimulation.
Further to the method, EEG signal may also be measured as
part of the method and as taught herein. In one embodiment,
EEG may be measured at the stimulation application site.
I0123. Further to the method, the at least one signal form
8 configured to provide analgesia for short-term pain relief
may comprise a periodic signal Such as, but not limited to,
a pulse train or a sinusoidal waveform. In one embodiment,
the periodic signal has frequencies between 1 Hz and 300
HZ, which is consistent with the physiologic stimulation
frequency range as taught in Some examples of the art. In
another embodiment, the periodic signal has frequencies
between 50 Hz, and 150 Hz. Such frequencies have been
shown to have the ability to modulate pain-related neu
rotransmitters. In exemplary embodiments, the periodic sig
nal has a frequency of approximately 60 Hz or approxi
mately 120 Hz. Such frequencies may relieve pain in
fibromyalgia.
0.124. Further to the embodiments, the periodic signal
may have amplitudes between -10 volts and +10 volts. In an
exemplary embodiment, the periodic signal has minimum
amplitude of -1 volts and maximum amplitude of +1 Volt.
Further still, the at least one signal form conceived to
provide analgesia for short-term pain relief 8 comprises a
direct current (DC) signal.
0.125 Further to the embodiments, the at least one signal
form 8 configured to provide analgesia for short-term pain
relief may be applied during periods of rest time before or
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after sequences of bursts of at least one signal form 7
configured to provide long-term treatment of a neurological
condition.

0126 Further to the method, the composite electrical
stimulation signal 6 is conducted along at least one current
pathway through at least one portion of a brain. Such
portions of a brain may be selected from a group consisting
of but not limited to the parietal lobes, somatosensory
cortex, thalamus, prefrontal cortex, primary motor cortex,
secondary motor cortex, insula or default mode network.
Such current pathways may be created by placing at least
two electrical leads proximate to the portion of a brain to be
stimulated, as is previously taught herein. The method may
also be accomplished by applying a composite electrical
stimulation signal 6 using means that create at least a first
current pathway through at least a first portion of a brain for
providing long-term treatment of the neurological condition,
and at least a second current pathway through at least a
second portion of a brain for providing analgesia for short
term pain relief.
0127. Further to the method, the treatment of a neuro
logical condition may be accomplished by providing treat
ment applications of a composite electrical stimulation sig
nal 6 applied repeatedly over a period of time to cause a
lasting therapeutic effect. In one embodiment, treatment
applications are applied at least once a day, with at least one
day transpiring between treatment applications during which
time no electrical stimulation is applied to the patient 4. In
another embodiment, treatment applications are applied
twice in a calendar week, with two days transpiring between
treatment applications. Further to the embodiment, treat
ment is applied over a range of 8 to 24 weeks. In a preferred
embodiment, treatment comprises 24 treatment applications
applied over a period of 12 consecutive weeks. The method
is further accomplished when additional treatment applica
tions are applied as necessary to further treat the fibromyal
gia and achieve more satisfactory alleviation of symptoms.
0128. In a preferred embodiment, a method of treating a
neurological condition is accomplished using a composite
electrical stimulation signal 6 which comprises a signal 7
configured to provide long-term treatment of the neurologi
cal condition, and which further comprises a signal 8 con
figured to provide analgesia for short-term pain relief
wherein the signal 8 configured to provide analgesia for
short-term pain relief comprises a train of both 60 Hz
positive pulses and 60 Hz negative pulses, in which the
positive pulses have a minimum amplitude of 0 Volts and a
maximum amplitude of 0.5 volts and the negative pulses
have a maximum amplitude of 0 Volts and a minimum
amplitude of -0.5 volts, and in which the positive and
negative pulses alternate and are equally spaced in time;
wherein the signal 7 configured to provide long-term treat
ment of the neurological condition comprises a monopolar
pulse train of frequency sufficient to reduce tissue imped
ance, in which the pulse train amplitude has a minimum
value of 0 volts, a maximum value of 0.2 volts, a frequency
of approximately 15,000 Hz and a duty cycle of approxi
mately 37.5% and is amplitude modulated to form a rect
angular waveshape with frequencies ranging from 7 Hz to
12 Hz as a function of time; wherein each application of the
electrical stimulation comprises the burst sequence consist
ing of a first burst lasting three minutes and comprising the
signal 8 configured to provide analgesia for short-term pain
relief, a second burst lasting 30 seconds and comprising the

Nov. 24, 2016

signal 7 configured to provide long-term treatment of the
neurological condition with frequencies Sweeping from 7 HZ
to 12 HZ over approximately equal periods of time during
the burst, a third burst lasting 60 seconds and comprising the
signal 8 configured to provide analgesia for short-term pain
relief, a fourth burst lasting 60 seconds and comprising the
signal 7 configured to provide long-term treatment of the
neurological condition with frequencies Sweeping from 7 HZ
to 12 HZ over approximately equal periods of time during
the burst, a fifth burst lasting 60 seconds and comprising the
signal 8 configured to provide analgesia for short-term pain
relief, a sixth burst lasting 90 seconds and comprising the
signal 7 configured to provide long-term treatment of the
neurological condition with frequencies Sweeping from 7 HZ
to 12 HZ over approximately equal periods of time during
the burst, and a seventh burst lasting three minutes and
comprising the signal 8 configured to provide analgesia for
short-term pain relief; wherein the electrical stimulation is
conducted along a current pathway created between a first
electrical lead placed proximate to International 10-20 site
PZ, and a second electrical lead placed proximate to the right
ear lobe; in which the treatment applications are applied
twice in a calendar week, with two days transpiring between
treatment applications; and in which the treatment applica
tions are applied over a period of 12 consecutive weeks.
I0129. Further to the present invention, and with reference
to FIG. 3, an electrical stimulation apparatus is provided
comprising a composite electrical signal generator 9, with
the composite electrical signal generator 9 further compris
ing at least one apparatus 10 adapted to generate an electrical
signal form configured to provide long-term treatment of a
neurological condition and further comprising at least one
apparatus 11 adapted to generate an electrical signal form
configured to provide analgesia for short-term pain relief.
0.130. In one embodiment, an apparatus 10 adapted to
generate electrical stimulation signal forms configured to
provide long-term treatment of a neurological condition is
further configured to provide an electrical stimulation signal
comprising a tissue transmission signal and a therapeutic
signal. Further to the embodiment, an apparatus 11 adapted
to generate electrical stimulation signal forms configured to
provide analgesia for short-term pain relief further is further
configured to provide an electrical stimulation signal con
figured to modulate one or more neurotransmitters associ
ated with analgesia.
I0131 Numerous electrical circuit embodiments may be
used to accomplish the apparatus. In one embodiment illus
trated in FIG. 4, the composite electrical signal generator
apparatus 13 may comprise a computing device Such as a
microcontroller 14 configured to manage timing of the
therapy application and to control timed Switching between
periods of application of an electrical signal form configured
to provide long-term treatment of a neurological condition,
an electrical signal form configured to provide analgesia for
short-term pain relief, and application of no signal to accom
plish periods of rest.
0.132. The apparatus 13 may further comprise a first
signal circuit 15 configured to generate an electrical signal
form configured to provide long-term treatment of a neuro
logical condition. The apparatus 13 may further comprise a
second-signal circuit 16 configured to generate an electrical
signal form configured to provide analgesia for short-term
pain relief.
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0133. The apparatus 13 may further comprise a multi
plexer circuit 17, which may be controlled by the micro
controller 14 to selectively transmit output from either the
first-signal circuit 15 or the second-signal circuit 16 onto a
signal transmission conductor 18, or to transmit no signal to
the signal transmission conductor 18 for accomplishing
periods of rest. The apparatus 13 may further comprise a
mixer circuit 19, which may be controlled by the microcon
troller 14 to simultaneously transmit output from both the
first-signal circuit 15 and the second-signal circuit 16 onto a
signal transmission conductor 18, or to transmit no signal to
the signal transmission conductor 18 for accomplishing
periods of rest.
0134. The embodiments might further comprise at least
one signal conditioning circuit 20 configured to transform
the generated signal waveforms into stimulation signals with
desired Voltage, amperage and power characteristics. Such
signal conditioning circuit 20 may comprise an amplifier
circuit. In the embodiments, the apparatus may further
comprise any one or more circuit elements selected from but
not limited to the group of circuit elements consisting of an
EEG amplifier configured to measure EEG signals, a filter
circuit configured to reduce electrical noise in EEG signals,
an isolation amplifier configured to protect human Subjects,
an analog-to-digital interface configured to convert analog
EEG signals to digital signals, and an isolated power Supply
configured to provide circuit power and human Subject
protection.
0135 The embodiments may further comprise one or
more conductors 2 electrically coupled to the signal trans
mission conductor 18 and configured to deliver the com
posite electrical signal from the composite electrical signal
generator apparatus to a subject 4 being stimulated.
0136. The embodiments may further comprise at least
one safety circuit 21. In one such embodiment, a safety
circuit 21 comprises a redundant timer circuit used to assure
that an expected amount of stimulation time is not exceeded.
Such safety circuit 21 may be used in case of a microcon
troller 14 failure while the stimulation signal is being
transmitted to the signal transmission conductor 18. Such
safety circuit 21 might be configured to open the signal
transmission conductor 18 if an expected maximum stimu
lation time is exceeded, thus preventing the Subject 4 from
receiving more stimulation than desired.
0.137 The embodiments may further comprise a user
interface 12, Such as but not limited to a software graphic
user interface which provides user guidance for providing a
composite stimulation signal.
0.138. The invention is not limited in any way to the
embodiments disclosed herein. In this regard, no attempt is
made to show structural details of the disclosed apparatuses
or process details of the disclosed methods in more detail
than is necessary for a fundamental understanding of the
disclosed apparatuses and methods. The description is
intended only to make apparent to those skilled in the art
how the several forms of the invention may be embodied in
practice.
Example 1
0.139. A clinical trial entitled “The Clinical Effect of
Low-Intensity Electromagnetic Field Neurostimulation in
Fibromyalgia Syndrome Patients' (Hargrove et al. Pain
Med. 2012 Jan: 13(1): 115-24. ClinicalTrials.gov registration
NCT01180244) was conducted at two independent sites. It
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utilized a randomized, double-blind sham controlled design
with a subsequent unblinded crossover of sham treated
patients.
0140. The study was conducted on patients diagnosed
with fibromyalgia using the American College of Rheuma
tology's 1990 (ACR 1990) classification criteria. Patients
received either active treatment using a signal form taught
herein, or a sham treatment. Treatment was applied twice a
week for a period of eleven consecutive weeks. Total stimu
lation exposure at each treatment application was 3.0 min
utes, for a total exposure time over the course of therapy of
66 minutes. A uniform protocol including signal form,
exposure time and exposure location was applied during
each study visit, as described below. Since the signal forms
taught herein are not perceived by patients, the sham con
dition was created by simply not turning on the signal.
(0.141. The specific protocol for the NCT01180244 study
was as follows:

0142. A total of 86 patients were enrolled in the study. Of
these, no patients in the active treatment group Voluntarily
discontinued therapy. Seven patients in the sham group
discontinued therapy citing no therapeutic benefit as the
reason. One patient in the intervention group failed to return
for end of therapy assessment and examination (i.e. was lost
to follow-up), therefore no end of therapy data was gathered.
0.143 Eligibility of volunteers was assessed at screening
that included a medical and Surgical history, a physical
examination, completion of patient self-report question
naires designed to provide some of the study’s outcome
measures, an EEG test and a dolorimeter assessment of

tender points (TePs) at 18 sites per the ACR 1990 classifi
cation criteria. Key Subject inclusion criteria included hav
ing a confirmed diagnosis of primary fibromyalgia per the
ACR 1990 classification criteria and ongoing symptoms
lasting at least 48 months with no recent remission or
significant change. Patients with other pain related diagno
ses, chronic neurological disorder or significant systemic
disorders were excluded from enrollment. Subjects with
psychiatric disorders, other than depression and anxiety,
requiring separate treatment were also excluded from enroll
ment.

0144. Outcome measures included the Fibromyalgia
Impact Questionnaire (FIO), the number of positive tender
points (TePs) (i.e. those tender points eliciting a painful
response with less than 4 kg/cm2 dolorimeter pressure), and
the tender point pressure pain threshold (PPT) derived by
summing the dolorimetry pain thresholds for each of the 18
TePs assessed. In addition, all patients completed neurop
sychiatric assessments, health outcomes questionnaires and
a seven-question Sleep Visual Analog Scale (Sleep VAS)
questionnaire.
0145 Safety was evaluated by monitoring for patient
reported adverse events (AES) during the study and at
post-therapy examination. In addition, a Subset of patients
participating in long-term follow-up was asked to disclose
any significant changes in health. No treatment emergent
serious adverse effects were encountered over the course of

the study. No adverse events or negative effects of treatment
were discovered in long-term follow-up. Patient-reported
AEs during the course of therapy were minor and resolved
without medical intervention.

0146 Efficacy was evaluated following repeat screening
procedures on each patient conducted 1-2 weeks after the
completion of therapy. These procedures included a physical
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examination, TeP and PPT evaluation, and repeat comple
tion of outcome measures questionnaires. No assessment
was done during the therapy period.
0147 Table 1 provides a brief summary of outcomes data
relevant to efficacy for the treatment of pain in fibromyalgia.
Data provided is a measure of post-therapy to baseline
differences presented as raw data, with percent change and
p-values (statistical significance) in parentheses.

0148 Table 2 reports group comparison statistics for 30
patients in the control (sham) group that underwent Subse
quent unblinded crossover to actual intervention. The elec
trical stimulation signal protocol used was the same as that
used on the original active treatment group and taught
herein. It should be noted that some of the patients in the
control group chose not to participate in the unblinded
COSSOW

phase.

TABLE 1.

Treatment outcomes related to pain in fibromyalgia
Outcome Measure

Intervention

Sham

Group

Group

Conclusion

Post therapy change and percent –7.3 (42%, -0.1 (1%,
improvement in number of positive p < 0.001) p = 0.67)
TePs, paired t-test individual
averages (range 0-18)
Post-therapy group difference in
6.9 (41%, p < 0.001)
number of positive TePs, t-test on

Patient self-reported
improvement in pain, as
evidenced by changes in pain
VAS, shows significant
improvement in the intervention
group, and no significant
change in the sham group.
Group outcome differences are
significant.
Patient self-reported
improvement in fibromyalgia
specific symptoms, as
evidenced by changes in the
overall FIQ score, shows
significant improvement in the
intervention group, and no
significant change in the sham
group. Group outcome
differences are significant.
The therapy resulted in
significant improvement in the
number of tender points in the
intervention group, and no
change in the sham group.
Group outcome differences are

group averages

significant.

Post-therapy change and percent -1.8 (27%, -0.4 (7%,
improvement in pain VAS assessed p < 0.001) p = 0.20)
by the FIQ, paired t-test individual
averages (range 0-10)
Post-therapy group difference in
1.3 (20%, p = 0.02)
pain VAS assessed by the FIQ, t
test on group averages

Post-therapy change and percent -13.6 (22%, –4.3 (7%,
improvement in overall FIQ score, p < 0.001) p = 0.054)
paired t-test individual averages
(range 0-100)
Post-therapy group difference in
9.3 (15%, p = 0.01)
overall FIQ score, t-test on group
averages

Post therapy change and percent +19.1 (52%, -2.7 (-7%, The therapy resulted in
improvement in PPT, paired t-test p < 0.001) p = 0.04)
significant improvement in the
individual averages (range 9-72)
PPT in the intervention group.
Post-therapy group difference in
21.8 (59%, p<0.001) The sham group showed a
PPT, t-test on group averages
significant worsening in PPT (p =
0.04). Group outcome
differences are significant.
Post-therapy change and percent -105.8
-30.0 (11%, Patient self-reported
improvement in sleep VAS score, (53%,
p = 0.13)
improvement in sleep, as
paired t-test individual averages p < 0.001)
evidenced by changes in the
(range 0-600)
sleep VAS score, shows
Post-therapy group difference in
75.8 (42%, p = 0.01) significant improvement in the
sleep VAS score, t-test on group
intervention group, and no
averages
significant change in the sham
group. Group outcome
differences are significant.

TABLE 2

Group comparison of unblinded crossover patients
N - 30 test on group averages
Post-Sham
to
Crossover

Baseline

Post-Sham

Crossover

Baseline to
Post-Sham

Outcome Measure

Mean SD

Mean SD

Mean SD

p-value

p-value

FIQ Pain VAS score
Overall FIQ score

6.1 2.4
55.6 (17.3

5.9 (2.7
50.9 (20.2

4.5 2.8)
37.6 (20.9)

O.84
O.38

O.O6
O.O3
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TABLE 2-continued
Group comparison of unblinded crossover patients
N = 30, t-test on group averages
Post-Sham
to
Crossover

Baseline

Post-Sham

Crossover

Baseline to
Post-Sham

Outcome Measure

Mean SD

Mean SD

Mean SD

p-value

p-value

Number of positive TePs
PPT, t-test on group

16.8 1.9)
38.9 11.9)

16.6 (1.9)
35.99.5

7.6 (4.6)
61.0 (7.7

0.79
O.29

<0.001
<0.001

averages
SD—standard deviation

0149 Additional study data show that the electrical
stimulation therapy also resulted in significant improve
ments in other symptoms associated with fibromyalgia.
There were no site, evaluator or treating clinician effects that
altered the results.
0150. A follow-up study was completed with a cohort of
study participants (Hargrove et al. Arch Phys Med Rehabil.
2012 October; 93(10): 1868-71). The follow up included a
symptom Survey and the FIQ, and was intended to collect
information concerning the long-term safety and efficacy of
the electrical stimulation treatment taught herein.
0151. Of the original 86 participants, 39 patients who
were able to be contacted were mailed follow-up surveys. A

study and 31.8 at follow-up. One-way repeat measures
ANOVA using the Holm-Sidak correction for multiple com
parisons showed both end of study and follow-up scores
were significantly different from baseline (P<0.001).
Although follow-up scores were numerically Superior to end
of study scores, this difference was not significant (P=0.35).
The FIQ score differences between baseline and end of
study, and baseline and follow-up, were calculated for each
respondent and found to be significantly correlated (R=0.78,
P<0.001). Table 3 presents results of similar analyses per
formed on the FIQ's subscales.
TABLE 3

Analysis of FIQ outcomes
Respondent
FIQ Scores

Significance
ANOVA

45-month Baseline-

Baseline EOS follow-up EOS
Total FIQ Score
Pain WAS

Fatigue VAS
Sleep VAS
Stiffness WAS

Anxiety VAS
Depression VAS

S2.6
6.0

35.7
4.0

31.8
3.6

Baseline-

Correlation’

follow-up

R-value P-value

P<0.001
P < 0.01

P - O.OO1
P - O.OO1

O.78
O.78

<0.001
<0.001

7.7

6.O

4.53

P < 0.01

P - 0.001

O.69

<0.001

7.9
6.8
4.0
3.5

6.2
4.7
1.8
1.7

S.O
4.0
2.6
1.9

P < 0.01
P < 0.01
P<0.001
P<0.001

PPP=
P-

O.S1
O.49
O.70
O.63

<0.01
O.O1
<0.001
<0.001

O.OO1
O.OO1
0.03
O.O1

End of study
*Correlation between changes from baseline at EOS and at follow-up
Long-term improvement since EOS is significant at P = 0.02

series of Likert Scale-based questions asked patients to
report on symptom changes for tenderness, general pain,
sleep, fatigue (energy), and depression/mood at both the end
of study and currently. Patients were also asked to indicate
how medicine use for both fibromyalgia pain and sleep had
changed, and were asked a series of questions about their use
of tricyclic antidepressants, selective serotonin reuptake
inhibitors, pregabalin, dulloxetine and milnacipran since
completing the study. Patients were also asked to indicate
how their need to visit physicians or other caregivers spe
cifically for fibromyalgia changed.
0152. Of 39 mailed surveys, 25 were returned (64%). The
average respondent age was 59 years (range 39-71). All
respondents were female. The average time since comple
tion of therapy was 45 months (range 31-60).
0153. In terms of efficacy, the mean total FIQ score for
the respondent group was 52.6 at baseline, 35.7 at end of

0154 Table 4 provides a summary of patient responses
for the level of improvement experienced in tenderness,
pain, sleep, fatigue/energy, and depression/mood at end of
study (EOS); their current condition for the same symptoms:
and analysis of reported duration of response.
0155 While there is an inherent bias in a survey method
of this type, there does seem to be evidence of maintenance
of improvement in fibromyalgia symptoms well beyond the
end of the electrical stimulation treatment period. In addition
to a Suggestion of long-term symptom improvement, there
was also evidence of reduction in both fibromyalgia medi
cation usage and health care resource utilization. Of those
who had reported using pain medicines, 76% reported either
reduced or eliminated medicine use for pain. Of those that
have taken sleep medicines, 44% reported either reduced or
eliminated medicine use for sleep. Finally, 71% of all
respondents indicate reduced or eliminated need to see
physicians or caregivers for fibromyalgia treatment.
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0156 With regard to safety, patients were asked to report
whether or not the therapy ever caused any pain or discom
fort, and whether they experienced any side effects. No
respondent reported experiencing any pain, discomfort or
previously unreported side effects following completion of
electrical stimulation therapy.
TABLE 4

Summary and analysis of patient responses for sympton improvement
Tenderness

Fatigue Depression
Pain Sleep (energy)
mood

Respondent reported
symptom change
at EOS
Much improved
Somewhat improved
No change

SO%
38%
13%

36%.
44%.
20%.

25%.
42%.
33%.

44%
32%
20%

32%
20%
28%

Got worse

O%

O%

0%

4%

4%

Does not apply

O%

O%.

8%

O%

16%

Reported state of
symptoms at

time of follow-up
More improved
Since EOS
Same improvement
as EOS

20%

28%.

13%.

36%

32%

36%

36%.

46%

20%

28%

Improved for a time,

40%

24%.

8%

24%

12%

4%

12%.

29%.

20%

12%

O%

O%.

490

O%

16%

62%

75%

87%

749

80%

10%

0%

59

but returned

Never changed got
WOSe

Does not apply
Duration of

Symptom
Improvements

Reported’

Maintained to date

More than two years
1-2 years

Less than one year
Unknown duration

38%

59,

79%

10%

0%

59

O%

6%

11%

59
20%

End of study
*Among long-term responders
Incremental duration of effect was not evaluated for tenderness and depressionimood

0157. Further, some of the survey’s symptom questions
gave respondents the option to report any worsening of
symptoms. No respondent reported worsening of tenderness,
pain or sleep (0%). A worsening of fatigue was reported by
one patient (4%) and worsening of depression was reported
by one other (4%).
0158. Further to this study, EEG coherence analysis was
performed to evaluate functional neural network connectiv
ity in patient participants. Coherence, which is a measure of
the correlation of relative amplitude and phase between pairs
of EEG signals, is an established measure of functional
network connectivity, and is ideally Suited for providing
temporally stable measures. Changes in EEG coherence in
subjects who received the electrical stimulation treatment
taught herein were compared to those Subjects who received
sham.

0159 Procedurally, eyes-closed resting EEG was col
lected at 19 of the International 10-20 electrode sites for

each subject at baseline and within one week of electrical
stimulation therapy completion. To reduce coherence bias
ing due to cortical volume conduction over short spatial
distances, only non-neighboring electrode pairings (N=118)

were analyzed. Fibromyalgia symptomatology was assessed
with the FIQ and the Short Form-36 (SF-36).
(0160 Baseline coherence was consistent between treat
ment groups in 112 of the 118 possible electrode pairs (95%,
P<0.05). Analysis found that group mean change from
baseline coherence decreased 67% at end of study in the
active treatment group, while a corresponding decrease of
only 18% was seen in the sham group (P<0.001). In the
active treatment group, 79 out of 118 electrode pairings
achieved at least a 50% mean change from baseline
response, compared to only 9 in the sham group (X2-86.3,
P<0.001). Following active treatment using electrical stimu
lation methods as taught herein, a number of significant
positive correlations in both inter- and intra-hemispherical
electrode pairings were found between change from baseline
coherence and improvements in total FIQ score and SF-36
domains. Further analysis showed improvements in FIO
score and pain VAS scale were greatest in Subjects showing
reductions in brain functional network connectivity based on
changes in EEG coherence.
Example 2
0.161. A second clinical trial entitled “A Double-Blinded,
Randomized, Sham-Controlled, Proof of Concept Phase 2
Study Exploring the Safety and Efficacy of RINCE Tech
nology for the Treatment of Patients with Fibromyalgia”
(ClinicalTrials.gov registration NCT01825954), was con
ducted at a single site on 45 evaluable fibromyalgia patients.
Like the trial of Example 1, this trial also utilized a ran
domized, blinded and sham controlled design. Fibromyalgia
patient entry criteria were also similar to those used in
Example 1.
0162 The primary outcome measure for this study was
the patients’ pain level as assessed by 0-100 mm visual
analog scale (VAS) recordings. At each visit, the patient
recorded their 24-hour recall pain score and at every other
visit they also provided their seven-day recall pain score.
Additional outcome measures included the patient global
impression of change (PGIC), the revised Fibromyalgia
Impact Questionnaire (FIO-R), the Jenkins sleep scale, the
Beck depression inventory (BDI-II), the Multiple Ability
Self-report Questionnaire (MASQ) and the Mental Clutter
Scale (MCS).
0163 The electrical stimulation signals applied to
patients receiving active treatment included an electrical
signal form configured for treating fibromyalgia or other
central pain related neurological conditions as taught herein
(i.e., "Signal 1), a composite electrical stimulation signal
configured to provide long-term treatment of a neurological
condition and provide analgesia for short-term pain relief
(i.e., "Signal 2), and a signal configured only to provide
analgesia for short-term pain relief (i.e., “Signal 3').
0164. Two separate groupings of therapeutic approach
were studied. In a first grouping, 22 fibromyalgia patients
were treated with either Signal 1 or a sham, essentially
repeating the protocol of the trial of Example 1. Patients
were randomized into three groups: Group 1A received 8
weeks of Signal 1 treatment followed by 4 weeks of sham;
Group 1B received 12 weeks of Signal 1 treatment; and
Group 1C received 12 weeks of sham. Sham consisted of no
signal delivery. The daily treatment delivery schedule and
signal delivery timing on all patients was the same as that
used in the trial of Example 1.
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0165. In this first grouping of patients, primary outcomes
analysis confirmed the therapeutic benefit which was also
seen in the study of Example 1. Table 5 presents a summary
of first grouping post-therapy to baseline differences in
24-hour pain VAS, comparing the various treatment groups.
The table entries represent group mean raw changes in pain
VAS measures.
TABLE 5

Analysis of 24-hour pain VAS outcomes in first patient grouping
Group 1B vs.
Group 1C
Change in Pain VAS
PValue

Group 1A vs.
Group 1C

-25.2

-19.9

O.O23

OO67

Group 1B vs.
Group 1A
-53
O.64

0166 As seen in Table 5, the reduction in pain as evi
denced by change in 24-hour pain VAS was significantly
greater in patients receiving 12 weeks of Signal 1 treatment
versus those patients receiving sham (P=0.023). Patients
receiving 8 weeks of Signal 1 had a greater reduction in pain
over those receiving sham, but the difference missed sig
nificance (P=0.067). The difference in pain reduction levels
was not significant between patients receiving 12 weeks of
Signal 1 versus those receiving 8 weeks of Signal 1 plus 4
weeks of sham (P=0.64), although the longer application of
Signal 1 did produce numerically Superior results.
0167. In a second grouping, 23 additional fibromyalgia
patients were treated with a combination of Signals 2 and 3.
These patients were randomized into three groups: Group
2A received 8 weeks of the composite Signal 2 treatment
followed by 4 weeks of the short-term analgesic Signal 3:
Group 2B received 12 weeks of Signal 2 only; and Group 2C
received 12 weeks of Signal 3 only. The daily treatment
delivery schedule and signal delivery timing on all patients
was the same as that used in the trial of Example 1 and in
the first grouping of patients in Example 2.
0168 Table 6 presents a summary of second patient
grouping post-therapy to baseline differences in 24-hour
pain VAS, comparing the various treatment groups. The
table entries represent group mean raw changes in pain VAS
CaSUS.

TABLE 6

Analysis of 24-hour pain VAS outcomes in second patient grouping
Group 2B vs.
Group 2C
Change in Pain VAS
PValue

+26.4
-O.O17

Group 2A vs.
Group 2C
+37.8
-OOO1

Group 2B vs.
Group 2A
-11.4
0.27

0169. While all patients in this second grouping received
pain reduction over baseline as a result of stimulation signal
therapy, the data of Table 6 show that those patients receiv
ing 12 weeks of only the short-term analgesic Signal 3 had
greater pain reduction over those patients receiving 12
weeks of the composite Signal 2, with significance at
P=0.017. Similarly, 12 weeks of short-term analgesic Signal
3 produced significantly greater pain reduction over those
patients receiving 8 weeks of the composite Signal 2 fol
lowed by 4 weeks of the analgesic Signal 3 (P=0.001). Those
patients receiving 12 weeks of only the composite signal had
numerically greater pain reduction over those receiving 8

weeks of the composite signal followed by 4 weeks of the
analgesic signal, however the difference was not significant
(P=0.27).
0170 The results from the second grouping of patients
Suggest that the use of a composite signal as taught herein
can produce greater levels of immediate pain relief, as
evidenced by 24-hour pain recall measures, over signals that
are configured only for long-term treatment of fibromyalgia
or other central pain related neurological conditions as
taught herein. Further evidence of the mechanistic differ
ences between the signals taught herein was gained by
analyzing long-term patient outcomes. It would be expected
that those patients who received only Signal 3, and who
accordingly received the greatest level of pain reduction as
evidenced by second grouping 24-hour pain VAS outcomes,
would not have a corresponding long-term therapeutic
effect. This would hypothetically be due to the lack of
therapy with stimulation signals featuring components
intended to provide long-term treatment of fibromyalgia or
other central pain related neurological conditions, as taught
herein. In Support of this, follow up data was gathered from
a cohort of patients studied in Example 2. In the cohort,
second grouping patients who received only Signal 3 did not
maintain any long-term pain reduction benefit. Their follow
up pain VAS scores were on average 14.8% worse than they
were at baseline. In comparison, the cohort of patients who
received any level of Signals 1 and 2 were still on average
53.8% improved over baseline. The average time of follow
up in these patients was approximately 4.5 months after
cessation of therapy.
0171 For both groupings, safety was assessed through
routine collection of vital signs, routine collection of treat
ment emergent adverse events, and review of neurocognitive
functioning results (MASQ and MCS) and mood scores
(BDI-II). A consistent finding in the Example 2 study was an
extremely low rate of adverse events related to the therapy.
Consistent with the study of Example 1, there were very few
adverse event categories that seemed to correlate with the
stimulation therapy. Out of the patients enrolled in Example
2, there were no terminations for adverse events, and no
serious adverse events. 97% of all adverse events were mild

or moderate, and the vast majority appeared to be related to
the underlying fibromyalgia condition. The only adverse
event terms that may have been linked to therapy delivery
were headache, Vertigo and scalp dermatitis related to the
use of electrically conductive gel at the interface between
the patient’s skin and the conductor's electrode.
What is claimed is:

1. A method of treating a neurological condition in a
patient, the method comprising the step of applying an
electrical stimulation from conductors to the patient’s head
at a stimulation application site, the electrical stimulation
comprising a composite electrical signal further comprising
at least one signal form configured to provide long-term
treatment of the neurological condition and at least one
signal form configured to provide analgesia for short-term
pain relief.
2. The method of claim 1, in which the electrical stimu

lation is subthreshold for detection by the patient.
3. The method of claim 1, in which the at least one signal
form configured to provide long-term treatment of the
neurological condition and the at least one signal form
configured to provide analgesia for short-term pain relief are
applied simultaneously during a treatment application.
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4. The method of claim 1, in which the at least one signal
form configured to provide long-term treatment of the
neurological condition and the at least one signal form
configured to provide analgesia for short-term pain relief are
applied at alternating times during a treatment application.
5. The method of claim 1, in which the at least one signal
form configured to provide long-term treatment of the
neurological condition comprises an electrical signal con
figured to treat an abnormal brain condition associated with
the neurological condition.
6. The method of claim 1, in which the at least one signal
form configured to provide analgesia for short-term pain
relief comprises an electrical signal configured to stimulate
modulation of one or more neurotransmitters associated with

analgesia.
7. The method of claim 6, in which the modulation is

selected from a group consisting of the release, expression,
uptake, increased production, reduced production, inhibition
or elimination of neurotransmitters.

8. The method of claim 6, in which the neurotransmitters

are selected from a group consisting of serotonin, norepi
nephrine, glutamate, N-Methyl-D-aspartic acid, Substance
P. gama-aminobutyric acid, various nucleotides or dop
amine.

9. The method of claim 1, in which the condition is

selected from a group of neurological conditions consisting
of but not limited to, fibromyalgia, central sensitivity,
central pain, abnormal neural network connectivity, com
plex regional pain syndrome, phantom pain, irritable bowel
syndrome, temporomandibular disorder, myofascial pain
syndrome, regional soft-tissue pain syndrome, neuropathic
pain, osteoarthritis, back pain, post-operative pain, depres
Sion, tension-type headaches or migraine headaches.
10. The method of claim 1, in which the at least one signal
form configured to provide long-term treatment of the
neurological condition comprises a tissue transmission com
ponent and a therapeutic component.
11. The method of claim 10, in which the tissue trans

mission component comprises a pulse train of frequency
Sufficient to reduce tissue impedance between the conduc
tors and the patient’s brain.
12. The method of claim 11, in which the pulse train
amplitude has a minimum value of 0 volts and a maximum
value of 1 volt.

13. The method of claim 11, in which the pulse train
amplitude has a maximum value of 0.2 volts.
14. The method of claim 11, in which the pulse train
frequency is between 10,000 Hz and 20,000 Hz.
15. The method of claim 11, in which the pulse train
frequency is approximately 15,000 Hz.
16. The method of claim 11, in which the pulse train is
monopolar.
17. The method of claim 11 in which the pulse train is
pulse width modulated to create a variable duty cycle of on
time and off time.

18. The method of claim 17, in which the pulse train duty
cycle is between 20% and 60%.
19. The method of claim 17, in which the pulse train duty
cycle is approximately 37.5%.
20. The method of claim 11, in which the pulse train is
amplitude modulated to create a waveshape comprising an
amplitude envelope.
21. The method of claim 20, in which the waveshape
forms a therapeutic component.
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22. The method of claim 20, in which the amplitude
envelope forms a rectangular wave.
23. The method of claim 20, in which the amplitude
envelope forms a sinusoidal wave.
24. The method of claim 20, in which the amplitude
envelope forms a composite of multiple sinusoidal waves.
25. The method of claim 24, in which the multiple
sinusoidal waves have individual frequencies between 1 Hz
and 30 HZ.

26. The method of claim 20, in which the waveshape has
a frequency between 1 Hz and 30 Hz.
27. The method of claim 20, in which the waveshape has
a frequency between 7 Hz and 12 Hz.
28. The method of claim 20, in which the frequency of the
waveshape changes as a function of stimulation delivery
time.

29. The method of claim 20, in which the waveshape is a
rectangular wave with frequencies ranging from 7 Hz to 12
HZ as a function of time.

30. The method of claim 11, in which the pulse train has
an amplitude with minimum value of 0 Volts and maximum
value of 0.2 volts, a frequency of approximately 15,000 Hz
and a duty cycle of approximately 37.5%.
31. The method of claim 1, in which the electrical

stimulation includes a sequencing step in which an electrical
signal is applied in bursts for at least two burst periods with
at least one rest period comprising no stimulation in between
each pair of bursts.
32. The method of claim 31, in which each burst period
ranges in time from 1 second to 5 minutes.
33. The method of claim 31, in which each burst period
ranges in time from 30 seconds to 2 minutes.
34. The method of claim 31, in which each rest period
ranges in time from 1 second to 5 minutes.
35. The method of claim 31, in which each rest period is
60 seconds.

36. The method of claim 31, further comprising measur
ing the patient's EEG signal during the rest period.
37. The method of claim 36, in which the EEG is

measured at the stimulation application site.
38. The method of claim 36, further comprising measur
ing the patient's EEG signal for a period of rest prior to a
first burst of stimulation signal.
39. The method of claim 38, in which the period of rest
prior to a first burst ranges in time from 1 second to 5
minutes.

40. The method of claim 38, in which the period of rest
prior to a first burst is 3 minutes.
41. The method of claim 36, further comprising measur
ing the patient's EEG signal for a period of rest after a final
burst of stimulation signal.
42. The method of claim 41, in which the period of rest
after a final burst ranges in time from 1 second to 5 minutes.
43. The method of claim 41, in which the period of rest
after a final burst is 3 minutes.

44. The method of claim 31, wherein the sequencing step
comprises a burst and rest time sequence consisting of a first
three minute period of rest;
applying a first burst of the electrical stimulation signal
for 30 seconds;

after applying the first burst, ceasing application of the
electrical stimulation signal for a second period of rest
lasting 60 seconds;
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after the second period of rest, applying a second burst of
electrical stimulation signal for 60 seconds;
after applying the second burst, ceasing application of the
electrical stimulation signal for a third period of rest
lasting 60 seconds;
after the third period of rest, applying a third burst of the
electrical stimulation signal for 90 seconds; and
after applying the third burst, ceasing application of the
electrical stimulation signal for a fourth period of rest
lasting three minutes.
45. The method of claim 44, further comprising measur
ing the patient's EEG signal during at least one period of
rest.

46. The method of claim 44, in which the stimulation

burst comprises a pulse train, wherein said pulses have
amplitude having a minimum value of 0 Volts, a maximum
value of 0.2 volts, a frequency of approximately 15,000 Hz
and a duty cycle of approximately 37.5%.

47. The method of claim 44, in which the stimulation

signal burst is amplitude modulated to form rectangular
waveshapes, with said waveshapes having frequencies
sweeping from 7 Hz to 12 Hz over approximately equal
periods of time during the burst.
48. The method of claim 31, further comprising perform
ing the applying and sequencing steps repeatedly over a
period of time.
49. The method of claim 48, in which the applying and
sequencing steps are performed at least once a day, with at
least one day transpiring between applications.
50. The method of claim 48, in which the applying and
sequencing steps are performed twice in a calendar week,
with two days transpiring between applications.
51. The method of claim 48, in which the applying and
sequencing steps are performed repeatedly over a period
ranging from 8 to 12 consecutive weeks.
52. The method of claim 48, in which the applying and
sequencing steps are performed repeatedly over a period of
12 consecutive weeks.

53. The method of claim 48, in which the applying and
sequencing steps are performed 24 times over the period of
time.

54. The method of claim 53, further comprising perform
ing the applying and sequencing steps additional times to
further treat the neurological condition and achieve more
satisfactory alleviation of symptoms.
55. The method of claim 1, in which the at least one signal
form configured to provide analgesia for short-term pain
relief comprises a periodic signal.
56. The method of claim 55, in which the periodic signal
is a pulse train.
57. The method of claim 55, in which the periodic signal
is a sinusoidal waveform.

58. The method of claim 55, in which the periodic signal
has frequencies between 1 Hz and 300 Hz.
59. The method of claim 55, in which the periodic signal
has frequencies between 50 Hz and 150 Hz.
60. The method of claim 55, in which the periodic signal
has a frequency of approximately 60 Hz.
61. The method of claim 55, in which the periodic signal
has a frequency of approximately 120 HZ.
62. The method of claim 55, in which the periodic signal
has amplitudes between -10 volts and +10 volts.

63. The method of claim 55, in which the periodic signal
has minimum amplitude of -1 volts and maximum ampli
tude of +1 volt.

64. The method of claim 1, in which the at least one signal
form configured to provide analgesia for short-term pain
relief is applied during periods of rest time before or after
bursts of at least one signal form configured to provide
long-term treatment of a neurological condition.
65. The method of claim 1, in which the at least one signal
form configured to provide analgesia for short-term pain
relief comprises a direct current (DC) signal.
66. The method of claim 1, in which the applying step
includes the step of placing conductors to create a current
pathway through at least one portion of the patient’s brain.
67. The method of claim 66, in which the portion of a
brain is selected from a group consisting of the parietal
lobes, somatosensory cortex, thalamus, prefrontal cortex,
primary motor cortex, secondary motor cortex, insula or
default mode network.

68. The method of claim 66, wherein the conductors are

placed proximate to the portion of the brain to be stimulated.

69. The method of claim 66, in which the conductors are
noninvasive.

70. The method of claim 66, wherein the placing step
comprises placing a first conductor proximate to the parietal
lobes along the median plane, and a second conductor
proximate to the right ear.
71. The method of claim 66, wherein the placing step
comprises placing a first conductor proximate to Interna
tional 10-20 site PZ, and a second conductor proximate to the
right ear lobe.
72. The method of claim 1, wherein the applying step
comprises applying electrical stimulation through conduc
tors that create at least a first current pathway through at
least a first portion of the patient’s brain for providing
long-term treatment of the neurological condition, and at
least a second current pathway through at least a second
portion of the patient's brain for providing analgesia for
short-term pain relief.
73. The method of claim 72, wherein the conductors

comprise at least two electrical leads placed proximate to the
portion of the patient’s brain to be stimulated.
74. The method of claim 73, in which the conductors are
noninvasive.

75. A method of treating a neurological condition in a
patient, the method comprising:
placing a first electrical lead on the patient's head proxi
mate to International 10-20 site PZ;

placing a second electrical lead proximate to the patients
right ear lobe;
applying a composite electrical stimulation signal com
prising a signal configured to provide long-term treat
ment of the neurological condition and a signal con
figured to provide analgesia for short-term pain relief;
wherein the signal configured to provide analgesia for
short-term pain relief comprises a pulse train of both 60
Hz positive pulses and 60 Hz negative pulses;
wherein the positive pulses have a minimum amplitude of
0 volts and a maximum amplitude of 0.5 volts:
wherein the negative pulses have a maximum amplitude
of 0 volts and a minimum amplitude of -0.5 volts:
wherein the positive and negative pulses alternate and are
equally spaced in time;
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wherein the signal to provide long-term treatment of the
neurological condition comprises a monopolar pulse
train of frequency Sufficient to reduce tissue imped
ance,

wherein the pulse train amplitude has a minimum value of
0 volts, a maximum value of 0.2 volts, a frequency of
approximately 15,000 Hz, and a duty cycle of approxi
mately 37.5%;
wherein the pulse train is amplitude modulated to form a
rectangular waveshape with frequencies ranging from 7
HZ to 12 Hz, as a function of time;

sequencing application of the electrical stimulation signal
in a burst and rest time sequence consisting of
a first burst comprising the signal configured to provide
analgesia for short-term pain relief, lasting three min
utes;

a second burst comprising the signal configured to pro
vide long-term treatment of the neurological condition,
lasting 30 seconds, with frequencies Sweeping from 7
HZ to 12 Hz over approximately equal periods of time
during the burst;
a third burst comprising the signal configured to provide
analgesia for short-term pain relief, lasting 60 seconds;
a fourth burst comprising the signal configured to provide
long-term treatment of the neurological condition, last
ing 60 seconds, with frequencies Sweeping from 7 HZ
to 12 HZ over approximately equal periods of time
during the burst;
a fifth burst comprising the signal configured to provide
analgesia for short-term pain relief, lasting 60 seconds;
a sixth burst comprising the signal configured to provide
long-term treatment of the neurological condition, last
ing 90 seconds, with frequencies sweeping from 7 Hz
to 12 HZ over approximately equal periods of time
during the burst; and
a seventh burst comprising the signal configured to pro
vide analgesia for short-term pain relief, lasting three
minutes;

wherein the electrical stimulation is conducted along a
current pathway created between the first electrical lead
placed proximate to International 10-20 site PZ, and the
second electrical lead placed proximate to the right ear
lobe:

performing the placing, applying and sequencing steps
twice in a calendar week, with at least one day trans
piring between treatment applications, over a period of
12 consecutive weeks.

76. An electrical stimulation apparatus comprising an
electrical signal generator adapted to provide an electrical
signal form configured to provide long-term treatment of a
neurological condition and to provide an electrical signal
form configured to provide analgesia for short-term pain
relief.

77. The apparatus of claim 76, in which the electrical
signal generator further comprises at least one microcon
troller configured to generate composite signal waveforms
and coupled to at least one signal conditioning circuit
configured to transform the composite signal waveforms
into stimulation signals.
78. The apparatus of claim 77, in which the at least one
signal conditioning circuit comprises an amplifier circuit.
79. The apparatus of claim 76, further comprising any one
or more circuit elements selected from the group of circuit
elements consisting of an EEG amplifier configured to

measure EEG signals, a filter circuit configured to reduce
electrical noise in EEG signals, an isolation amplifier con
figured to protect human Subjects, an analog-to-digital inter
face configured to convert analog EEG signals to digital
signals, and an isolated power Supply configured to provide
circuit power and human Subject protection.
80. The apparatus of claim 76, further comprising at least
two electrical leads for providing a composite stimulation
signal current pathway between the electrical signal genera
tor and a tissue to be stimulated.

81. The apparatus of claim 76, further comprising a user
interface.

82. The apparatus of claim 81, further comprising a
Software graphic user interface which provides user guid
ance for providing a composite stimulation signal.
83. A method for treating a neurological condition in a
patient, the method comprising: applying an electrical
stimulation signal from conductors to the patient’s head at a
stimulation application site, wherein the electrical stimula
tion signal comprises a tissue transmission component and a
therapeutic component; and sequencing the electrical stimu
lation signal in bursts for at least two burst periods with at
least one rest period comprising no stimulation in between
each pair of bursts.
84. The method of claim 83, in which the electrical

stimulation signal is subthreshold for detection by the
patient.
85. The method of claim 83, in which the tissue trans

mission component comprises a pulse train of frequency
Sufficient to reduce tissue impedance between the conduc
tors and the patient’s brain.
86. The method of claim 85, in which the pulse train
amplitude has a minimum value of 0 volts and a maximum
value of 1 volt.

87. The method of claim 85, in which the pulse train
amplitude has a maximum value of 0.2 volts.
88. The method of claim 85, in which the pulse train
frequency is between 10,000 Hz and 20,000 Hz.
89. The method of claim 85, in which the pulse train
frequency is approximately 15,000 Hz.
90. The method of claim 85, in which the pulse train is
monopolar.
91. The method of claim 85, in which the pulse train is
pulse width modulated to create a variable duty cycle of on
time and off time.

92. The method of claim 91, in which the pulse train duty
cycle is between 20% and 60%.
93. The method of claim 91, in which the pulse train duty
cycle is approximately 37.5%.
94. The method of claim 85, in which the pulse train is
amplitude modulated to create a waveshape comprising an
amplitude envelope.
95. The method of claim 94, in which the waveshape
forms a therapeutic component.
96. The method of claim 94, in which the amplitude
envelope forms a rectangular wave.
97. The method of claim 94, in which the amplitude
envelope forms a sinusoidal wave.
98. The method of claim 94, in which the amplitude
envelope forms a composite of multiple sinusoidal waves.
99. The method of claim 98, in which the multiple
sinusoidal waves have individual frequencies between 1 Hz
and 30 HZ.
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100. The method of claim 94, in which the waveshape has
a frequency between 1 Hz and 30 Hz.
101. The method of claim 94, in which the waveshape has
a frequency between 7 Hz and 12 Hz.
102. The method of claim 94, in which the frequency of
the waveshape changes as a function of stimulation delivery
time.

103. The method of claim 94, in which the waveshape is
a rectangular wave with frequencies ranging from 7 Hz to 12
HZ as a function of time.

104. The method of claim 85, in which the pulse train has
an amplitude with minimum value of 0 Volts and maximum
value of 0.2 volts, a frequency of approximately 15,000 Hz
and a duty cycle of approximately 37.5%.
105. The method of claim 83, in which each burst period
ranges in time from 1 second to 5 minutes.
106. The method of claim 83, in which each burst period
ranges in time from 30 seconds to 2 minutes.
107. The method of claim 83, in which each rest period
ranges in time from 1 second to 5 minutes.
108. The method of claim 83, in which each rest period is
60 seconds.

109. The method of claim 83, further comprising mea
Suring the patient’s electroencephalogram (EEG) signal dur
ing the rest period.
110. The method of claim 109, in which the EEG is

measured at the stimulation application site.
111. The method of claim 109, further comprising mea
suring the patient's EEG signal for a period of rest prior to
a first burst of stimulation signal.
112. The method of claim 111, in which the period of rest
prior to a first burst ranges in time from 1 second to 5
minutes.

113. The method of claim 111, in which the period of rest
prior to a first burst is 3 minutes.
114. The method of claim 109, further comprising mea
suring the patient's EEG signal for a period of rest after a
final burst of Stimulation signal.
115. The method of claim 114, in which the period of rest
after a final burst ranges in time from 1 second to 5 minutes.
116. The method of claim 114, in which the period of rest
after a final burst is 3 minutes.

117. The method of claim 83, wherein the sequencing step
comprises a burst and rest time sequence consisting of
a first three minute period of rest;
applying a first burst of the electrical stimulation signal
for 30 seconds;

after applying the first burst, ceasing application of the
electrical stimulation signal for a second period of rest
lasting 60 seconds;
after the second period of rest, applying a second burst of
the electrical stimulation signal for 60 seconds;
after applying the second burst, ceasing application of the
electrical stimulation signal for a third period of rest
lasting 60 seconds;
after the third period of rest, applying a third burst of the
electrical stimulation signal for 90 seconds; and
after applying the third burst, ceasing application of the
electrical stimulation signal for a fourth period of rest
lasting three minutes.
118. The method of claim 117, in which the stimulation

burst comprises a pulse train, wherein said pulses have
amplitude having a minimum value of 0 Volts, a maximum
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value of 0.2 volts, a frequency of approximately 15,000 Hz
and a duty cycle of approximately 37.5%.
119. The method of claim 117, in which the stimulation

signal burst is amplitude modulated to form rectangular
waveshapes, with said waveshapes having frequencies
sweeping from 7 Hz to 12 Hz over approximately equal
periods of time during the burst.
120. The method of claim 83, in which the applying step
includes the step of placing conductors to create a current
pathway through at least one portion of the patient’s brain.
121. The method of claim 120, in which the portion of a
brain is selected from a group consisting of the parietal
lobes, somatosensory cortex, thalamus, prefrontal cortex,
primary motor cortex, secondary motor cortex, insula or
default mode network.

122. The method of claim 120, wherein the conductors are

placed proximate to the portion of the brain to be stimulated.
123. The method of claim 120, wherein the placing step
comprises placing a first conductor proximate to the parietal
lobes along the median plane, and a second conductor
proximate to the right ear.
124. The method of claim 120, wherein the placing step
comprises placing a first conductor proximate to Interna
tional 10-20 site PZ, and a second conductor proximate to the
right ear lobe.
125. The method of claim 83, in which the conductors are
noninvasive.

126. The method of claim 83, further comprising per
forming the applying and sequencing steps repeatedly over
a period of time.
127. The method of claim 126, in which the applying and
sequencing steps are performed at least once a day, with at
least one day transpiring between applications.
128. The method of claim 126, in which the applying and
sequencing steps are performed twice in a calendar week,
with two days transpiring between applications.
129. The method of claim 126, in which the applying and
sequencing steps are performed repeatedly over a period
ranging from 8 to 24 consecutive weeks.
130. The method of claim 126, in which the applying and
sequencing steps are performed repeatedly over a period of
12 consecutive weeks.

131. The method of claim 126, in which the applying and
sequencing steps are performed 24 times over the period of
time.

132. The method of claim 131, further comprising per
forming the applying and sequencing steps additional times
to further treat the neurological condition and achieve more
satisfactory alleviation of symptoms.
133. The method of claim 83, in which the neurological
condition is selected from a group consisting of hyperalge
sia, central pain, central sensitivity, chronic pain, abnormal
brain network connectivity, neuropathic pain, central pain
arising from chronic osteoarthritis, central pain arising from
chronic back pain, chronic headache, migraine headache or
depression.
134. A method of treating a neurological condition in a
patient, the method comprising:
placing a first conductor on the patient's head proximate
to International 10-20 site PZ;

placing a second conductor proximate to the patients
right ear lobe;
applying an electrical stimulation signal between the first
and second conductors, the electrical stimulation signal

US 2016/0339241 A1

Nov. 24, 2016
22

comprising a tissue transmission component further
comprising a monopolar pulse train of frequency Suf
ficient to reduce tissue impedance between the conduc
tors and the patient’s brain;
wherein the pulse train amplitude has a minimum value of
0 volts, a maximum value of 0.2 volts, a frequency of
approximately 15,000 Hz, and a duty cycle of approxi
mately 37.5%;
wherein the pulse train is amplitude modulated to form a
rectangular waveshape with frequencies ranging from 7
HZ to 12 Hz, as a function of time;

sequencing application of the electrical stimulation signal
in a burst and rest time sequence consisting of
a first three minute period of rest;
after the first period of rest, applying a first burst of the
electrical stimulation signal for 30 seconds, with
frequencies sweeping from 7 Hz to 12 Hz over
approximately equal periods of time during the burst;
after applying the first burst, ceasing application of the
electrical stimulation signal for a second period of
rest lasting 60 seconds;
after the second period of rest, applying a second burst
of the electrical stimulation signal for 60 seconds,
with frequencies sweeping from 7 Hz to 12 Hz over
approximately equal periods of time during the burst;
after applying the second burst, ceasing application of
the electrical stimulation signal for a third period of
rest lasting 60 seconds;
after the third period of rest, applying a third burst of
the electrical stimulation signal for 90 seconds, with
frequencies sweeping from 7 Hz to 12 Hz over
approximately equal periods of time during the burst;
and

after applying the third burst, ceasing application of the
electrical stimulation signal for a fourth period of
rest lasting three minutes;
performing the placing, applying and sequencing steps
twice in a calendar week, with at least one day trans
piring between treatment applications, over a period of
12 consecutive weeks.

135. A method for treating fibromyalgia in a patient, the
method comprising: applying an electrical stimulation signal
from conductors to the patient's head at a stimulation
application site, wherein the electrical stimulation signal
comprises a tissue transmission component and a therapeutic
component; and sequencing the electrical stimulation signal
in bursts for at least two burst periods with at least one rest
period comprising no stimulation in between each pair of
bursts.

136. The method of claim 135, in which the electrical

stimulation signal is subthreshold for detection by the
patient.
137. The method of claim 135, in which the tissue

transmission component comprises a pulse train of fre
quency Sufficient to reduce tissue impedance between the
conductors and the patient’s brain.
138. The method of claim 137, in which the pulse train
amplitude has a minimum value of 0 volts and a maximum
value of 1 volt.

139. The method of claim 137, in which the pulse train
amplitude has a maximum value of 0.2 volts.
140. The method of claim 137, in which the pulse train
frequency is between 10,000 Hz and 20,000 Hz.

141. The method of claim 137, in which the pulse train
frequency is approximately 15,000 Hz.
142. The method of claim 137, in which the pulse train is
monopolar.
143. The method of claim 137, in which the pulse train is
pulse width modulated to create a variable duty cycle of on
time and off time.

144. The method of claim 143, in which the pulse train
duty cycle is between 20% and 60%.
145. The method of claim 143, in which the pulse train
duty cycle is approximately 37.5%.
146. The method of claim 143, in which the pulse train is
amplitude modulated to create a waveshape comprising an
amplitude envelope.
147. The method of claim 146, in which the waveshape
forms a therapeutic component.
148. The method of claim 146, in which the amplitude
envelope forms a rectangular wave.
149. The method of claim 146, in which the amplitude
envelope forms a sinusoidal wave.
150. The method of claim 146, in which the amplitude
envelope forms a composite of multiple sinusoidal waves.
151. The method of claim 150, in which the multiple
sinusoidal waves have individual frequencies between 1 Hz
and 30 HZ.

152. The method of claim 146, in which the waveshape
has a frequency between 1 Hz and 30 Hz.
153. The method of claim 146, in which the waveshape
has a frequency between 7 Hz and 12 Hz.
154. The method of claim 146, in which the frequency of
the waveshape changes as a function of stimulation delivery
time.

155. The method of claim 146, in which the waveshape is
a rectangular wave with frequencies ranging from 7 Hz to 12
HZ as a function of time.

156. The method of claim 137, in which the pulse train
has an amplitude with minimum value of 0 volts and
maximum value of 0.2 volts, a frequency of approximately
15,000 Hz, and a duty cycle of approximately 37.5%.
157. The method of claim 135, in which each burst period
ranges in time from 1 second to 5 minutes.
158. The method of claim 135, in which each burst period
ranges in time from 30 seconds to 2 minutes.
159. The method of claim 135, in which each rest period
ranges in time from 1 second to 5 minutes.
160. The method of claim 135, in which each rest period
is 60 seconds.

161. The method of claim 135, further comprising mea
Suring the patient’s electroencephalogram (EEG) signal dur
ing the rest period.
162. The method of claim 161, in which the EEG is

measured at the stimulation application site.
163. The method of claim 161, further comprising mea
suring the patient's EEG signal for a period of rest prior to
a first burst of stimulation signal.
164. The method of claim 163, in which the period of rest
prior to a first burst ranges in time from 1 second to 5
minutes.

165. The method of claim 163, in which the period of rest
prior to a first burst is 3 minutes.
166. The method of claim 161, further comprising mea
suring the patient's EEG signal for a period of rest after a
final burst of Stimulation signal.

US 2016/0339241 A1

167. The method of claim 166, in which the period of rest
after a final burst ranges in time from 1 second to 5 minutes.
168. The method of claim 166, in which the period of rest
after a final burst is 3 minutes.

169. The method of claim 135, wherein the sequencing
step comprises a burst and rest time sequence consisting of
a first three minute period of rest;
applying a first burst of the electrical stimulation signal
for 30 seconds;

after applying the first burst, ceasing application of the
electrical stimulation signal for a second period of rest
lasting 60 seconds;
after the second period of rest, applying a second burst of
the electrical stimulation signal for 60 seconds;
after applying the second burst, ceasing application of the
electrical stimulation signal for a third period of rest
lasting 60 seconds;
after the third period of rest, applying a third burst of the
electrical stimulation signal for 90 seconds; and
after applying the third burst, ceasing application of the
electrical stimulation signal for a fourth period of rest
lasting three minutes.
170. The method of claim 169, in which the stimulation

burst comprises a pulse train, wherein said pulses have
amplitude having a minimum value of 0 Volts, a maximum
value of 0.2 volts, a frequency of approximately 15,000 Hz
and a duty cycle of approximately 37.5%.

171. The method of claim 169, in which the stimulation

signal burst is amplitude modulated to form rectangular
waveshapes, with said waveshapes having frequencies
sweeping from 7 Hz to 12 Hz over approximately equal
periods of time during the burst.
172. The method of claim 135, in which the applying step
includes the step of placing conductors to create a current
pathway through at least one portion of the patient’s brain.
173. The method of claim 172, in which the portion of a
brain is selected from a group consisting of the parietal
lobes, somatosensory cortex, thalamus, prefrontal cortex,
primary motor cortex, secondary motor cortex, insula or
default mode network.

174. The method of claim 172, wherein the conductors are

placed proximate to the portion of the brain to be stimulated.
175. The method of claim 172, wherein the placing step
comprises placing a first conductor proximate to the parietal
lobes along the median plane, and a second conductor
proximate to the right ear.
176. The method of claim 172, wherein the placing step
comprises placing a first conductor proximate to Interna
tional 10-20 site PZ, and a second conductor proximate to the
right ear lobe.
177. The method of claim 135, in which the conductors
are noninvasive.

178. The method of claim 135, further comprising per
forming the applying and sequencing steps repeatedly over
a period of time.
179. The method of claim 178, in which the applying and
sequencing steps are performed at least once a day, with at
least one day transpiring between applications.
180. The method of claim 178, in which the applying and
sequencing steps are performed twice in a calendar week,
with two days transpiring between applications.
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181. The method of claim 178, in which the applying and
sequencing steps are performed repeatedly over a period
ranging from 8 to 24 consecutive weeks.
182. The method of claim 178, in which the applying and
sequencing steps are performed repeatedly over a period of
12 consecutive weeks.

183. The method of claim 178, in which the applying and
sequencing steps are performed 24 times over the period of
time.

184. The method of claim 183, further comprising per
forming the applying and sequencing steps additional times
to further treat the fibromyalgia and achieve more satisfac
tory alleviation of symptoms.
185. A method of treating fibromyalgia in a patient, the
method comprising:
placing a first conductor on the patient's head proximate
to International 10-20 site PZ;

placing a second conductor proximate to the patients
right ear lobe;
applying an electrical stimulation signal between the first
and second conductors, the electrical stimulation signal
comprising a tissue transmission component further
comprising a monopolar pulse train of frequency Suf
ficient to reduce tissue impedance between the conduc
tors and the patient’s brain;
wherein the pulse train amplitude has a minimum value of
0 volts, a maximum value of 0.2 volts, a frequency of
approximately 15,000 Hz, and a duty cycle of approxi
mately 37.5%;
wherein the pulse train is amplitude modulated to form a
rectangular waveshape with frequencies ranging from 7
HZ to 12 Hz, as a function of time;

sequencing application of the electrical stimulation signal
in a burst and rest time sequence consisting of
a first three minute period of rest;
after the first period of rest, applying a first burst of the
electrical stimulation signal for 30 seconds, with
frequencies sweeping from 7 Hz to 12 Hz over
approximately equal periods of time during the burst;
after applying the first burst, ceasing application of the
electrical stimulation signal for a second period of
rest lasting 60 seconds;
after the second period of rest, applying a second burst
of the electrical stimulation signal for 60 seconds,
with frequencies sweeping from 7 Hz to 12 Hz over
approximately equal periods of time during the burst;
after applying the second burst, ceasing application of
the electrical stimulation signal for a third period of
rest lasting 60 seconds;
after the third period of rest, applying a third burst of
the electrical stimulation signal for 90 seconds, with
frequencies sweeping from 7 Hz to 12 Hz over
approximately equal periods of time during the burst;
and

after applying the third burst, ceasing application of the
electrical stimulation signal for a fourth period of
rest lasting three minutes;
performing the placing, applying and sequencing steps
twice in a calendar week, with at least one day trans
piring between treatment applications, over a period of
12 consecutive weeks.
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